

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|--|-----------|---|
| (51) International Patent Classification ⁶ : C12N 15/09, A61K 39/395, G01N 33/569, 33/68, A01K 67/027, C07K 14/16, A61K 47/48, C12N 5/10, A61K 38/19, C07K 14/715 | A2 | (11) International Publication Number: WO 98/00535 (43) International Publication Date: 8 January 1998 (08.01.98) |
| (21) International Application Number: PCT/US97/12701 (22) International Filing Date: 27 June 1997 (27.06.97) (30) Priority Data: 60/020,830 28 June 1996 (28.06.96) US 60/027,931 9 October 1996 (09.10.96) US 60/036,729 24 January 1997 (24.01.97) US (71) Applicants (for all designated States except US): DANA-FARBER CANCER INSTITUTE [US/US]; 44 Binney Street, Boston, MA 02115 (US). LEUKOSITE, INC. [US/US]; 215 First Street, Cambridge, MA 02142 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): SODROSKI, Joseph, G. [US/US]; 10 Ashland Street, Medford, MA 02155 (US). NEWMAN, Walter [US/US]; Apartment 3, 3 Durham Street, Boston, MA 02115 (US). CHOE, Hye-Ryun [KR/US]; 25 Webster Avenue #203, Somerville, MA 02143 (US). WU, LiJun [US/US]; 139 Oak Street, Reading, MA 01867 (US). GERARD, Norma [US/US]; 117 Walpole Street, Dover, MA 02030 (US). GERARD, Craig [US/US]; 117 Walpole Street, Dover, MA 02030 (US). | | (74) Agents: EISENSTEIN, Ronald, I. et al.; Dike, Bronstein, Roberts & Cushman, LLP, 130 Water Street, Boston, MA 02109 (US). (81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>Without international search report and to be republished upon receipt of that report.</i> |
| (54) Title: METHOD FOR INHIBITING HIV-1 INFECTION, DRUG SCREENS, AND METHODS OF DIAGNOSIS AND PROGNOSIS OF SUSCEPTIBILITY TO HIV INFECTION | | |
| (57) Abstract Novel β chemokine receptors that facilitate cellular entry of primary macrophage-tropic HIV-1 strains are described. CCR5 and CCR3 broadly facilitate entry of macrophage-tropic HIV-1 strains. A gp120 conformational binding site that is formed by the binding of gp120 and CD4 which permits binding of the complex to the chemokine receptors is also disclosed. Binding assays which permit the ready screening for molecules which affect the binding of gp120 and the chemokine are taught as well as specific targets for affecting the binding. | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the

| | | | | | | | |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | ML | Mali | TR | Turkey |
| BG | Bulgaria | HU | Hungary | MN | Mongolia | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MR | Mauritania | UA | Ukraine |
| BR | Brazil | IL | Israel | MW | Malawi | UG | Uganda |
| BY | Belarus | IS | Iceland | MX | Mexico | US | United States of America |
| CA | Canada | IT | Italy | NE | Niger | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NL | Netherlands | VN | Viet Nam |
| CG | Congo | KE | Kenya | NO | Norway | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NZ | New Zealand | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | PL | Poland | | |
| CM | Cameroon | KR | Republic of Korea | PT | Portugal | | |
| CN | China | KZ | Kazakhstan | RO | Romania | | |
| CU | Cuba | LC | Saint Lucia | RU | Russian Federation | | |
| CZ | Czech Republic | LI | Liechtenstein | SD | Sudan | | |
| DE | Germany | LK | Sri Lanka | SE | Sweden | | |
| DK | Denmark | LR | Liberia | SG | Singapore | | |
| EE | Estonia | | | | | | |

METHOD FOR INHIBITING HIV-1 INFECTION, DRUG SCREENS,
AND METHODS OF DIAGNOSIS AND PROGNOSIS OF
SUSCEPTIBILITY TO HIV-INFECTION

The present invention was funded in part by grants from the United States Government and it has certain rights to the inventions described herein.

5 The present invention claims priority from U.S. Provisional applications 60/027,931; 60/020,830 and 60/036,729; the content of all of these applications is incorporated herein by reference.

10 The present invention is directed to compounds and methods for inhibiting HIV infectivity, drug screens related thereto, and the diagnosis and prognosis of HIV infected individuals.

15 Human immunodeficiency viruses type 1 and type 2 (HIV-1 and HIV-2) are the etiologic agents of acquired immunodeficiency syndrome (AIDS) in humans (Barre-Sinoussi et al., 1984). AIDS results from the depletion of CD4-positive T lymphocytes in HIV-infected individuals (Fauci et al., 1984).

20 HIV-1 infects T lymphocytes, monocytes/macrophage, dendritic cells and, in the central nervous system, microglia (Gartner et al., 1986; Koenig et al., 1986; Pope et al., 1994; Weissman et al., 1995). All of these cells express the CD4 glycoprotein, which serves as the receptor for HIV-1 and HIV-2 (Dalgleish et al., 1984; Klatzman et al., 1984; Maddon et al., 1986). Efficient entry of HIV-1
25 into target cells is dependent upon binding of the viral exterior envelope glycoprotein, gp120, to the CD4-amino-terminal domain (McDougal et al., 1986; Helseth et al., 1990). After virus binding, the HIV-1 envelope
30 glycoproteins mediate the fusion of viral and host cell membranes to complete the entry process (Kowalski et al.,

1987; Stein et al., 1987; Helseth et al., 1990). Membrane fusion directed by HIV-1 envelope glycoproteins expressed on the infected cell surface leads to fusion with uninfected CD4-positive cells, resulting in syncytia (Lifson et al.,
5 1986; Sodroski et al., 1986).

Host cell factors in addition to CD4 appear necessary for effective HIV-1 envelope glycoprotein-mediated membrane fusion. Some human and animal cells have been shown to be resistant to HIV-1 infection and syncytium formation even
10 when human CD4 was expressed on the cell surface (Maddon et al., 1986; Ashorn et al., 1990; Chesebro et al., 1990; McKnight et al., 1994). Experiments with somatic cell hybrids suggested the possibility that a positive factor expressed in cells susceptible to syncytium formation could
15 complement the block to fusion in resistant cell types (Clapham et al., 1991; Dragic et al., 1992; Broder et al., 1993). HIV-1 variants exhibiting distinct differences in the ability to fuse with and to enter particular subsets of CD4-positive cells have been identified (Broder and Berger,
20 1995).

Discovery of factors that enhance HIV entry is important because it provides new areas for attacking the virus, new diagnostic and prognostic screens and can permit monitoring the susceptibility to HIV infection and/or
25 development of AIDS.

All primary clinical HIV-1 isolates, defined as viruses that have not been passaged on immortalized cell lines, replicate in primary monocytes/macrophages and in primary T lymphocytes. Two groups of primary HIV-1 isolates have been
30 defined, based on replication rate in peripheral blood mononuclear cells (PBMC) and the ability to infect and induce the formation of syncytia in immortalized CD4-

positive cell lines (Asjo et al., 1986; Cheng-Mayer et al., 1988; Fenyo et al., 1988; Tersmette et al., 1988).

Most primary HIV-1 viruses that initiate human infection and that persist throughout the course of
5 infection replicate to low levels in PBMC and do not replicate in immortalized T cell lines (Asjo et al., 1986; Schuitemaker et al., 1991; Schuitemaker et al., 1992; Connor et al., 1993, 1994a,b). These viruses are referred to herein as macrophage-tropic primary isolates (sometimes
10 referred to as "M"). In some HIV-1-infected individuals, viruses that replicate to higher levels in PBMC and that can infect and induce the formation of syncytia in immortalized CD4-positive cell lines emerge late in the course of infection (Asjo et al., 1986; Schuitemaker et al., 1992;
15 Connor et al., 1993, 1994a,b). These viruses will be referred to herein as T cell line-tropic primary viruses (sometimes referred to as "T"). The T cell line-tropic primary viruses, by virtue of their ability to replicate on some immortalized cell lines, serve as precursors to the
20 laboratory-adapted isolates, which have been extensively passaged on such cell lines. Laboratory adaptation, however, results in a loss of the ability of HIV-1 to replicate in primary monocyte/macrophage cultures (Schuitemaker et al., 1991; Chesebro et al., 1991;
25 Westervelt et al., 1992; Valentin et al., 1994). Thus, while all HIV-1 isolates replicate on primary T lymphocytes, three groups of virus variants can be defined based on the ability to replicate in primary monocyte/macrophages or in immortalized T cell lines: (1) macrophage-tropic primary
30 viruses that cannot infect T cell lines; (2) laboratory-adapted viruses that cannot infect primary monocytes/macrophages; and (3) T cell line-tropic primary

viruses that exhibit dual-tropism for these cell types.

Changes in the viral envelope glycoproteins, in particular in the third variable (V3) region of the gp120 exterior envelope glycoprotein, determine tropism-related phenotypes (Cheng-Mayer et al., 1990; O'Brien et al., 1990; Hwang et al., Westervelt et al., 1992; Chesebro et al., 1992; Willey et al., 1994). Amino acid changes in the V3 region (Helseth et al., 1990; Freed et al., 1991; Ivanoff et al., 1991; Bergeron et al., 1992; Grimailla et al., 1992; Page et al., 1992; Travis et al., 1992) and the binding of antibodies to this domain (Putney et al., 1986; Goudsmit et al., 1988; Linsley et al., 1988; Rusche et al., 1988; Skinner et al., Javeherian et al., 1989) have been shown to disrupt a virus entry process other than CD4 binding. The dependence of the phenotype resulting from V3 structural variation on the particular target cell suggested that the V3 region, which contains a surface-exposed, disulfide-linked loop (Leonard et al., 1990; Moore et al., 1994), might act in conjunction with target cell moieties to determine the efficiency of membrane fusion events.

Infection of macrophage-tropic primary HIV-1 isolates, but not that of a laboratory-adapted isolate, has been shown to be inhibited by the β -chemokines RANTES, MIP-1 α and MIP-1 β (Cocchi et al., 1995). High endogenous expression of these β -chemokines has been suggested to account for the *in vitro* resistance to HIV-1 infection of CD4-positive T cells from uninfected individuals with multiple sexual exposures to seropositive partners (Paxton et al., 1996). This resistance was only seen for macrophage-tropic and not T cell line-tropic viruses and was influenced by the structure of the third variable (V3) gp120 region of the infecting virus.

Recently, an "orphan" G protein-coupled seven transmembrane segment receptor, variously called *HUMSTR*, *LCR-1* or *LESTR* (now referred to as CXCR4) (Federspiel et al., 1993; Jazin et al., 1993; Loetscher et al., 1994) has been shown to allow a range of non-human, CD4-expressing cells to support infection and cell fusion mediated by laboratory-adapted HIV-1 envelope glycoproteins (Feng et al., 1996). Antibodies to *HUMSTR* blocked cell fusion and infection by laboratory-adapted HIV-1 isolates but not by macrophage-tropic primary viruses (Feng et al., 1996). While its natural ligand is currently unknown, *HUMSTR* exhibits sequence similarity to the receptor for interleukin-8, an alpha (CXC) chemokine) (Probst et al., 1992). The available data raised the possibility that at least one other molecule in addition to CD4 and distinct from CXCR4 facilitates the entry of primary, macrophage-tropic HIV-1 isolates, and that this molecule might be influenced by interaction with β -chemokines. Discovery of what the molecules are is desirable because it will help to modulate HIV cellular entry and develop more effective screening assays for inhibitors.

Chemokines are a family of structurally related peptides that recruit leukocytes to inflammatory lesions, induce release of granule contents from granulocytes, regulate integrin avidity, and in general exhibit proinflammatory properties. The α chemokines, or CXC chemokines, primarily activate neutrophils, while the β chemokines or CC chemokines, generally activate monocytes, lymphocytes, basophils and eosinophils (Baggiolini et al., 1994; Schall and Bacon, 1994). Receptors to these chemokines belong to the G protein-coupled receptor family. The large family of G protein-coupled receptors responds to

chemoattractants, neurotransmitters, peptide hormones, light and odorants. Amino acid identity among receptors that bind functionally related ligands ranges from 20-80% (Probst et al., 1992; Gerard and Gerard, 1994). Seven transmembrane
5 receptors that transduce their signals through heterotrimeric G proteins are used by leukocytes to respond to chemokines (Horuk et al., 1994). There are a number of closely related molecules in the CC chemokine receptor family but only six of these have been characterized in
10 ligand binding assays. These are designated CCR1, CCR2A, CCR2B, CCR3, CCR4 and CCR5. (They have previously been referred to is C-C CKR-1, -2A, -2B, 3, -4 and -5).

SUMMARY OF THE INVENTION

15 We have discovered that two β chemokine receptors facilitate cellular entry of primary macrophage-tropic HIV-1 strains. CCR5 and CCR3 broadly facilitate entry of macrophage-tropic HIV-1 strains.

We have also discovered that a gp120 conformational
20 binding site is formed by the binding of gp120 and CD4 which permits binding of the complex to the chemokine receptors.

We have also discovered binding assays which permit the ready screening for molecules which affect the binding of gp120 and the chemokine.

25 We have also discovered specific targets for affecting the binding.

BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A-1D show CAT activity in transfected HeLa
30 cells exposed to recombinant HIV-1 viruses. HeLa cells expressing human CD4 only are shown in Fig. 1A, CD4 and CCR1F are shown Fig. 1B, CD4 and CCR3 are shown in Fig. 1C

and CD4 and CCR5 are shown in Fig. 1D. The cells were exposed to recombinant viruses containing either no envelope glycoproteins (None) or envelope glycoproteins of the ADA, YU2, Br20-4 or HXBc2 isolates. The results of the CAT assay performed on the HeLa cell lysates are shown.

Figure 2 shows the effect of eotaxin on CCR3-mediated enhancement of YU2 recombinant virus. HeLa-CD4 cells transfected with plasmids expressing CD2, CCR1F, CCR3, CCR3F or CCR5 were incubated for one hour at 37°C with increasing amounts of eotaxin. Recombinant HIV-1 viruses containing the envelope glycoprotein of the YU2 macrophage-tropic primary isolate were added to the cells. CAT activity in the cell lysates was assessed 72 hours later.

Figures 3A-3D show the effect of CCR3, CCR5 and HUMSTSR expression on HIV-1 infection of Cf2Th canine thymocytes. Cf2Th canine thymocytes expressing human CD4 only (Fig 3A), CD4 and CCR3 (Fig 3B), CD4 and CCR5 (Fig 3C), or CD4 and HUMSTSR (Fig 3D) were infected with recombinant viruses containing the indicated envelope glycoproteins. The CAT assay results are shown. The results of a single experiment are shown. Comparable results were obtained in a repeat experiment.

Figures 4A-D show the effect of chemokine receptor expression on HIV-1 envelope glycoprotein-directed syncytium formation. HeLa cells expressing either no envelope glycoprotein (None) or the ADA, YU2, HXBc2 (ADA-V3), and HXBc2 (YU2-V3) envelope glycoproteins were cocultivated with HeLa-CD4 expressing CCR1, CCR3 (Fig 4B) or CCR5 (Figs. 4C and 4D). In one set of experiments, 2 µg/ml of the OKT4a antibody (Ortho Pharmaceuticals, Inc.) (Fig. 4D) was added at the beginning of the cocultivation. After 12 hours, the syncytia in the wells were counted. The results of a single

experiment are shown. The experiment was repeated with comparable results.

Fig. 5 shows the effect of eotaxin on CCR3-mediated enhancement of a recombinant virus containing amphotropic murine leukemia virus (A-MuLV). HeLa-CD4 cells which were transfected with plasmids expressing CD2, CCR1F or CCR3 under the same conditions as described in Figure 2. A chimeric HIV-1 virus containing the A-MuLV envelope glycoproteins were added to the cells. CAT activity in the cell lysate was assayed 72 hours later.

Figures 6A-C show the results of RT-PCR analysis of primary human brain cultures. Figure 6A shows detection of CCR5, CXCR4 and CCR3 transcripts in primary brain culture. Figure 6B shows detection of CCR3 in microglia but not other brain cell types by double immunofluoresence staining. Figure 6C shows detection of CCR3 in microglia.

Figure 7 shows identification of HIV-1 infected cells (YU2 or ADA infected) using GFP fluorescence in combination with cell specific markers as indicated.

Figure 8A-D show the efficiency of early phase virus replication as determined by measuring luciferase activity in primary brain culture.

In Figure 8A □ = no treatment, ■ = MIP-1 β , ▨ = Eotaxin, ▩ = SDF-1, ▧ = MCP-1. In Fig. 8B, the legend is the same, in addition, ▨ = anti-CCR3 (7B11) ■ (last solid box) = RANTES, ▩ = Eotaxin and MIP-1 β . In Fig. 8C the legend is the same, in this case, the only solid box represents RANTES. In Figure 8D, CAT activity is measured.

Figures 9A-E show inhibition of MIP-1 α and MIP-1 β binding to chemokine receptor-expressing cells by gp120 glycoproteins in the absence and presence of sCD4. Figure

9A shows the gp120 glycoproteins used in the study, indicating the conserved (C1-C5) and variable (V1-V5) regions of the native gp120 glycoproteins included in each of the proteins. The YU2 derivatives are chimeric molecules
5 containing YU2 sequences (shown in white) sufficient for CCR5 utilization [Choe, H., et al., Cell 85:1135-1148 (1996)], as well as sequences (shown in black) derived from the HXBc2 gp120 glycoprotein. Figure 9B shows the gp120 glycoprotein variants tested for ability to inhibit MIP-1 α
10 binding to CCR5F-L1.2 cells. In some experiments, sCD4 was included (at 100 nM final concentration unless otherwise noted). Figure 9C shows the effect of different doses of gp120 variants on MIP-1 α binding to CCR5F-L1.2 cells, in the absence (broken lines and open symbols) or presence
15 (solid lines and closed symbols) of 100 nM sCD4. Results are shown for the JR-FL (∇ , \blacktriangledown), BAL (Δ , \blacktriangle), YU2 Δ C1 Δ V1/2 Δ C5 (\bigcirc , \bullet), HXBc2 (\diamond), HXBc2 Δ C1 Δ V1/2/3 Δ C5 (\square) and YU2 Δ C1 Δ V1/2/3 Δ C5 (\diamond) glycoproteins. Figure 9D shows the gp120 variants tested, in the presence of 100 nM sCD4, for
20 ability to inhibit MIP-1 α binding to CCR1-L1.2 cells. Figure 9E shows gp120 variants tested for the ability to inhibit MIP-1 β binding to CCR5F-L1.2 cells in the absence and presence of 100 nM sCD4.

Figures 10A-C show comparison of two-domain and four-
25 domain soluble CD4 proteins for ability to inhibit MIP-1 α and MIP-1 β binding in the absence and presence of gp120 glycoproteins. Figure 10A shows the ability of D1D2 sCD4 (Δ , \blacktriangle), sCD4 (\bigcirc , \bullet), and soluble VCAM (\square , \blacksquare) to inhibit MIP-1 α binding to CCR5F-L1.2 cells in the absence (open

figures) and presence (closed figures) of 50 nM BAL gp120. Figure 10B shows the ability of D1D2 sCD4 (Δ , \blacktriangle) and sCD4 (\circ , \bullet) to inhibit MIP-1 β binding to CCR5F-L1.2 cells in the absence (open figures) and presence (closed figures) of 50 nM YU2 Δ C1 Δ V1/2 Δ C5 glycoprotein. Figure 10C shows the D1D2 sCD4 (Δ) and sCD4 (\circ) proteins ability to inhibit MIP-1 α binding to CC41-L1.2 cells at the indicated concentrations, in the absence of gp120 glycoproteins.

Figure 11 shows the effects of monoclonal antibodies on the inhibition of MIP-1 α binding to CCR5-expressing cells by gp120-sCD4 mixtures. Monoclonal antibodies (final concentration 500 nM) directed against gp120 (black shading), against CD4 (white shading) or against hybrid gp120-CD4 epitopes (grey shading) were tested for the ability to affect the inhibition of MIP-1 α binding to CCR5F-L1.2 cells by a mixture of the JR-FL gp120 glycoprotein (50 nM final concentration) and sCD4 (100 nM final concentration). The inhibition of MIP-1 α binding to CCR5F-L1.2 cells by the JR-FL gp120-sCD4 mixture in the absence of added antibody is also shown (hatched bar).

Figures 12A and B show binding of a radiolabeled macrophage-tropic primary virus gp120 derivative to CCR5-expressing cells. Figure 12A shows binding in the presence of 100 nM sCD4 of iodinated YU2 Δ C1 Δ V1/2 Δ C5 protein to CCR5F-L1.2 cells in the presence of increasing concentrations of either rYU2 Δ C1 Δ V1/2 Δ C5 protein (\circ) or HXBc2 Δ C1 Δ C5 protein (\square). Figure 12B shows binding in the presence of 100 nM sCD4 and 100 nM HXBc2 Δ C1 Δ C5 protein, of iodinated YU2 Δ C1 Δ V1/2 Δ C5 protein to CCRF-L1.2 cells in the

presence of the indicated concentrations of YU2ΔC1ΔV1/2ΔC5 protein (○), MIP-1α (◇), MIP-1β (□), RANTES (Δ) or YU2ΔC1ΔV1/2/3ΔC5 protein (X).

Figure 13 illustrates the results from a typical experiment for gp120/sCD4/CCR-binding using different amounts of membranes. The signal-to-noise ration (the ratio of total binding vs. non-specific binding) is shown on the top of each membrane concentration.

Figure 14 shows a Scatchard analysis using 5 μg membranes. Unlabeled JRFL-gp120 was added with increasing concentrations and the data analyzed by Scatchard analysis.

Binding affinity is $k_d=0.7$ nM. $\beta_{max}=1.6$ pmol/mg membrane.

Figure 15 shows that as a positive control, anti-CCR5 mAb 2D7 can efficiently inhibit the binding of 125 I-gp 120/sCD4 to CCR5.

Figure 16 is a comparison of the amino-terminal sequence of gpr15, gpr1, rCCR5 and CCR5 with the three conserved tyrosines (Y) shown in bold and reasonably conserved residues underlined. (MDPEETSVYLDY^YYATSPN (SEQ ID NO:1); MEDLEETLFE^YEFENYSYDL^YDYYSLESD (SEQ ID NO:2); MDYQVSSPT^YYDIDY^YTSEPC (SEQ ID NO:3); and MDYQVSSPI^YYDIN^YYTSEPC (SEQ ID NO:4)).

DETAILED DESCRIPTION OF THE INVENTION

We have now discovered that certain chemokine receptors are necessary for the infection of mammalian cells by HIV, particularly primary macrophage-tropic HIV-1 strains.

β-chemokine receptors are the receptors that bind β-chemokines. β-chemokines are a family of 8-10 kD secreted proteins. These proteins are characterized as β-chemokines

based on the absence of an intervening amino acid in the first of two conserved cysteine pairs (CC) as opposed to the α -chemokines that have an intervening amino acid in the first conserved cysteine pair (CXC). The chemokines include
5 macrophage inflammatory protein (MIP-1 α and MIP-1 β), RANTES (regulated on activation T expressed and secreted), monocyte chemotactic protein (MCP-1, MCP-2, MCP-3) and eotaxin. The class of surface proteins that bind certain of these chemokines have been identified and belong to the G-protein
10 -coupled seven transmembrane segment receptor family. The chemokine receptors (sometimes referred to as CXR- or CCR-) are characterized based on the specific chemokines they bind to. For example, CCR1 for example binds chemokines MIP-1 α and RANTES with high affinity. CCR2A and CCR2B for example
15 bind both MCP-1 and MCP-3. CCR3 for example binds chemokines such as eotaxin, RANTES, and MCP-3 with high affinity. CCR4 for example binds MIP-1 α , RANTES and MCP-1. CCR5 for example binds to chemokines such as MIP-1 α , MIP-1 β and RANTES. These represent the six β -chemokine receptors
20 that have currently been characterized.

The chemokine receptors share significant identity with each other. For example, CCR5 has significant identity to CCR2, sharing 71% identical amino acid residues. Its identity with other members of the family is about 50%.
25 CCR3 shares a 62% amino acid identity with CCR1 and identity with the other characterized receptors that ranges between about forty and fifty percent. CCR3 and CCR5 do not show as much identity to each other as they do to other chemokine receptors. Similarly, they do not show a chemokine affinity
30 pattern that is as similar to each other as it is to other members of the family. Yet, these two receptors facilitate

entry of primary HIV-1 macrophage-tropic strains.

In the initial assays where CCR3 was not as highly expressed as CCR5, CCR5 displayed a broader apparent host range than CCR3. However, in more sensitive assays we have
5 found that CCR3 facilitate HIV infection for all primary macrophage-tropic strains tested. Thus, CCR3 can interact with macrophage-tropic strains.

CCR5 is particularly involved with the following isolates: ADA, YU2, Br20-4, Br25-9, Rw20-5, Th966, TN243
10 and 89.6 More preferably the strains are ADA, YU2 BR20-4 and RW20-5.

CCR3 is particularly effective with the ADA and YU2 viruses and, to a lesser extent, with the 89.6 and ELI.

Whereas CCR5 is expressed in primary
15 monocyte/macrophage, primary T cells and granulocyte precursors [Deng, H.K., et al., 1996; Alkhatib, G., et al., 1996] and CXCR4 is expressed in a broad range of tissues and cell types including the brain and T cell [Feng, Y., et al, 1996], CCR3 expression appears more restricted, typically
20 eosinophils.

Microglia are the major targets for HIV infection of the central nervous system. Microglia express CCR3 as well as CCR5 Price, R.W., 1996; Watkins, B.A., et al., 1996; Takahashi, K., et al., 1990). Astrocytes are also infected,
25 but only at a very low level (Takahashi, K., et al., 1996; Harouse, J.M., et al., 1989; Tornatore C., et al., 1991). HIV-1 entry into microglia is CD4-dependent, (Jordan, et al., 1991) while entry into astrocytes and some neurally-derived cell lines is CD4-independent (Harouse, J.M., et
30 al., 1989; Tornatore C., et al., 1991). HIV-1 viruses that infect the CNS are M-tropic HIV-1 isolates, which represent the majority of primary isolates (Watkins, B.A., et al.,

1990; Korber, B.T.M., et al., 1994; Power, C., et al., 1994; Strizki, J.M., et al., 1996). Particular env sequences have been suggested as being associated with brain infection or dementia (Jirber, et al., 1994; Power, C., et al.,
5 although specific determinants of HIV-1 neurotropism have not been identified.

We have discovered that macrophage tropic isolates use CCR5 and CCR3 as co-receptors to infect microglia efficiently, whereas T-tropic isolates use CXCR4. For
10 example, blocking CCR5 or CCR3 can reduce microglia infection by M-tropic isolates by 70-80%.

It was previously reported that certain chemokines had different inhibitory effects on HIV activity. For example, RANTES was reported as having greater inhibitory activity
15 than the other chemokines identified. This indicates that the known chemokines receptors will not typically be solely responsible for enhancing infection. This is because CCR5 has a greater sensitivity to MIP-1 α than RANTES, yet RANTES exhibits a greater inhibitory activity than MIP-1 α .

20 Similarly CCR3 is responsive to RANTES but not to MIP-1 α .

Further, the distribution of these receptors differs. For example CCR5 is primarily expressed in promyeloblastic cells, particularly KG-1A, CD4-positive, and CD8-positive human PBMC and cells of the myeloid lineage. CCR3 as
25 discussed above is highly expressed in eosinophils with some expression in peripheral blood T lymphocytes. We have discovered that CCR3 is also expressed on dendritic cells, which is an important HIV reservoir. CCR3 is expressed at low levels on monocytes. The complete characterization of
30 the full tissue and cell-type distribution for these molecules awaits further studies.

Enhanced effectiveness in facilitating infections

appears to be dependent upon the number of receptors expressed. Assays which measure receptor level can be used in monitoring HIV-infected and high risk individuals. Differences in the levels of expression of these receptors in different individuals can account for some of the differences observed in onset of AIDS in HIV-infected individuals. Thus, determining the level of these receptors in HIV-infected individuals can be an important tool in determining whether an individual is at a greater risk for enhanced risk of infection and onset of AIDS. This knowledge can be used in determining the type of treatment for that individual.

The determination of the number of receptors present on the cells of an individual can readily be accomplished by standard means, for example, using FACS analysis or analysis of RNA levels. The level can be compared to a reference level, which can be determined by standard means. For example, one can prepare averages for individuals exhibiting early onset of AIDS, standard onset of AIDS and delayed onset of AIDS. This can also be done with respect to risk of HIV infection. Moreover, one can also take into account the presence of chemokines such as RANTES, MIP-1 α and/or MIP-1 β in relationship to the level of CCR3 and/or CCR5 present. These assays are further discussed below.

Viral variation, particularly that found in the gp120 glycoprotein sequences (28,29), dictates the specific chemokine receptor that can be utilized as an entry cofactor. M-tropic HIV-1 variants that use the chemokine receptor CCR5 as a coreceptor predominate during the asymptomatic stages of infection [Alkhatib, G., et al., *Nature Med* 2:1244-1247; Deng, H.K., et al., *Nature* 381:661-666 (1996); Doranz, B., et al., *Cell* 85:1149-1158 (1996);

Dragic, T., et al., *Nature* 381:667-673 (1996); Zhang, L., et al., *Nature* 383:768 (1996); Connor, R.I., et al., *J Exp Med* 185:621-628 (1997)]. CCR5 is expressed on T lymphocytes, monocytes/macrophages, brain microglia and dendritic cells
5 Wu, L., et al., *J Exp Med*; Granelli-Piperno, A., et al., *J Exp Med* 184:2433-2438 (1996); Raport, C., et al., *J Biol Chem* 271:1761-1766 (1996); He, J., et al., *Nature* 385:645-649 (1997)]. Individuals with defects in CCR5 expression are relatively resistant to HIV-1 infection [Liu, R., et al., *Cell* 86:367-378 (1996); Dean, M., et al., *Science* 273:1856-1862 (1996); Samson, M., et al., *Nature* 382:722-725 (1996)], indicating the critical contribution of this
10 chemokine receptor to virus transmission. Some M-tropic brain isolates of HIV-1 also use the chemokine receptor CCR3 as a coreceptor, consistent with the expression of CCR3 in brain microglia [He, J., et al., *Nature* 385:645-649 (1997)]. Later in the course of infection, T-tropic HIV-1 variants emerge that can use chemokine receptors, especially CXCR4, but also CCR3 and CCR2b, in addition to CCR5 [Zhang, L., et al., *Nature* 383:768 (1996); Connor, R.I., et al., *J Exp Med* 185:621-628 (1997); Simmons, G., et al., *J Virol* 70:8355-8360 (1996); Feng, Y., et al., *Science* 272:872-877 (1996); Schuitemaker, H. et al., *J Virol* 65:356-363 (1992)]. The
15 emergence of these viruses has been suggested to coincide with a less favorable clinical prognosis [Schuitemaker, H. et al., *J Virol* 65:356-363 (1992)], perhaps through an expansion of the range of infectable CD-4 positive T cell subsets [Bleul, C., et al., *Proc Natl Acad Sci USA*].
20

Another preferred embodiment of this invention is in
30 the diagnosis of susceptibility to HIV infection. The receptors, nucleotide sequences encoding receptors and antibodies that bind to receptors can be particularly useful

for diagnosis of susceptibility to infection where higher levels of the receptors indicate an increased risk of infection. The nucleotide sequences are known, for example the sequence for CCR3 is available from GenBank/EMBL/DDB under Accession Nos. U 49727 and U51241.

Using any suitable technique known in the art, such as Northern blotting, quantitative PCR, etc. the nucleotide sequences of the receptors or fragments thereof can be used to measure levels of chemokine receptor RNA expression.

Alternatively, the antibodies of the invention can be used in standard techniques such as Western blotting to detect the presence of cells expressing receptors and using standard techniques, e.g. FACS or ELISA, to quantify the level of expression.

One can inhibit infection by blocking CCR3 and/or CCR5. This can be accomplished by a range of different approaches. For example, antibodies, decoys, small molecules, antagonists, etc. One preferred approach is the use of antibodies to these receptors. Antibodies to these receptors can be prepared by standard means. For example, one can use single chain antibodies to target these receptors. An alternative strategy is to use CCR3 and CCR5 decoys. For example, one could prepare a decoy comprising the portion of these receptors present on the exterior of the cell membrane. Another strategy is to prepare soluble forms of these receptors using their known sequence. This can be done by standard means including using PCR to clone a gene, site-directed mutagenesis to make changes in the structure, deletions to make fragments, etc. as discussed below.

We have discovered that the HIV-1 gp120 envelope glycoprotein interacts with the CD4 receptor resulting in a

conformational change in the molecule which enhances the binding affinity of the gp120 protein for the chemokine receptor. This is exemplified herein with CCR5. Our results demonstrate that gp120 glycoproteins will

5 specifically interact with chemokine receptors, and that the interaction is dramatically enhanced by the formation of a complex with CD4. Interaction with the chemokine receptors is necessary for efficient membrane fusion and thereby viral infection. Accordingly, a new group of compounds that can

10 be used to inhibit infection (membrane fusion) is disclosed. For example, gp120 derivatives containing the chemokine binding site attached to a soluble CD4 molecule will have enhanced binding affinity to the chemokine receptors over the uncomplexed gp120. Molecules that preferentially bind

15 to these binding sites on gp120 will also prevent membrane fusion, for example, we have shown that the broadly neutralizing monoclonal antibody 17b can inhibit binding of gp120, e.g. the binding of the glycoprotein to CCR5.

Compounds that affect this interaction can be directly

20 screened for example using a direct binding assay such as exemplified in Figure 12. For example, one can label, e.g. radioactive or fluorescent, a gp120 protein or derivative and add soluble CD4. There are various soluble CD4s known in the art including a two-domain (D1D2 sCD4) and a four-

25 domain version. The labeled gp120, or derivative e.g. a conformational deletion such as YU2ΔC1ΔV1/2ΔC5 protein and soluble CD4 can be added to a medium containing a cell line expressing a chemokine receptor that that derivative will bind to. In this example, the derivative will bind to CCR5.

30 Alternatively, when using a derivative from a T cell tropic gp120 one would use a cell line that expresses CXCR4. Binding of the protein can then be directly measured. The

compound of interest can be added before or after the addition of the labeled gp120 or derivative and the effect of the derivative on binding can be determined by comparing the degree of binding in that situation against a base line standard with that gp120 or derivative, not in the presence of the compound.

One can use a stabilized complex of soluble CD4 and a gp120 molecule or a conformational derivative thereof as a decoy.

10 A preferred assay uses the labeled gp120, or derivative, for example a gp120 protein derived from an M-tropic strain such as JR-FL, iodinated using for instance solid phase lactoperoxidase (in one example having a specific activity of 20 $\mu\text{Ci}/\mu\text{g}$). The cell line containing the chemokine receptor in this example would be a CCR5 cell line, e.g. Ll.2 or membranes thereof. Soluble CD4 would be present. For screening small molecule antagonists, cell membranes are preferable, although similar procedures work with whole cells.

20 To test for compounds that affect binding the test molecule is added to the solution. Unlabeled gp120 can serve as a control. For example in a binding reaction in a final volume of 100 μl , 25 μl of soluble CD4 diluted in binding buffer (e.g. 50mM HEPES, pH 7.2, 1 mM CaCl_2 , 5 mM MgCl_2 , and 0.5% BSA) are added. 25 μl of binding buffer (for total binding) unlabeled gp120 at a final concentration of 100 nM (for non-specific binding), or test compounds at the desired concentrations are added. 25 μl of membranes (or whole cells), detected in binding buffer at the desired concentration are added, followed by 25 μl of labeled (e.g. ^{125}I -labeled) gp120 at a final concentration of 0.1 nM. The

contents are mixed and incubated at room temperature for 45-60 minutes. The reactions are then stopped. For example by transferring the mixture to GFB filter plates, pretreated with 0.3% PEI, washed (e.g., 2-3 times) with binding buffer containing e.g. 0.5 M NaCl in an automated cell harvester. The plates are dried, for example by heat lamp and the activity measured -- e.g. a MicroScint scintillation fluid added and the radioactivity counted for example on a β -counter. See Figures 13-15.

10 The binding assay can be adapted depending upon precisely what is being tested.

As used herein, the conformational derivative must contain a sufficient number of amino acid residues to define the binding site of the gp120 to the chemokine receptor and a sufficient number of amino acids to maintain the conformation of the peptide in a conformation that approximates that of wild-type gp120 bound to soluble CD4 with respect to the chemokine receptor binding site.

In one preferred embodiment, the derivative also contains a CD4 binding site (e.g. from the C3 region residues 368 and 370, and from the C4 region residues 427 and 457). As discussed herein, we have now discovered that the chemokine binding site is a discontinuous binding site that includes portions of the C2, C3, C4 and V3 regions. We also show herein certain examples of the gp120 derivatives that contain the binding site. By deletion of non-essential portions of the gp120 derivatives -- such as deletions of portions of non-essential variable regions (e.g. V1/V2) or protein in these constant regions (e.g. C1, C5) one can increase exposure of the chemokine binding site thereby enhancing the ability of the gp120 derivative to bind to the chemokine receptor, thereby inhibiting viral entry. Removal

of these regions is done while requiring the derivative to retain an overall conformation approximating that of the wild-type protein with respect to the native gp120 chemokine binding region when complexed to CD4. In addition, one can
5 remove glycosylation sites that are disposable for proper folding. Maintaining conformation can be accomplished by using linker residues that permit potential turns in the structure of the gp120 derivative to maintain the overall three-dimensional structure. Preferred amino acid residues
10 that can be used as linker include Gly and Pro. Other amino acids can also be used as part of the linker, e.g. Ala. Examples on how to prepare such peptides are described more fully in Wyatt, R., et al. *J. of Virol.* 69:5723-5733 (1995); Thali, M., et al., *J. of Virol.* 67:3978-3988 (1993); and
15 U.S. Application Serial No. 07/858,165 filed March 26, 1992 which are incorporated herein by reference. See for example Wyatt which teaches how to prepare V1/V2 deletions that retain the stem portion of the loop.

In one embodiment the gp120 derivative is designed to
20 be permanently attached at the CD4 binding site to sufficient domains of CD4 to create a conformation of the chemokine binding site approximating that of the native gp120 CD4 complex.

An alternative gp120 derivative is one wherein the
25 linkers used result in a conformation for the derivative so that the discontinuous binding site with the chemokine receptor approximates the conformation of the discontinuous binding site for the chemokine receptor in the wild-type gp120/CD4 complex. These derivatives can readily be made by
30 the person of ordinary skill in the art based upon the above described methodologies and screened in the assays shown herein to ensure that proper binding is obtained.

Stabilized forms of these complexes can readily be made, for example, by conjugates such as a poly(alkylene oxide) conjugate. The conjugate is preferably formed by covalently bonding the hydroxyl terminals of the
5 poly(alkylene oxide) and a free amino group in the gp120 derivative that will not affect the conformation of the discontinuous binding site. Other art recognized methods of conjugating these materials include amide or ester linkages. Covalent linkage as well as non-covalent conjugation such as
10 lipophilic or hydrophilic interactions can be used.

The conjugate can be comprised of non-antigenic polymeric substances such as dextran, polyvinyl pyrrolidones, polysaccharides, starches, polyvinyl alcohols, polyacryl amides or other similar substantially non-
15 immunogenic polymers. Polyethylene glycol (PEG) is preferred. Other poly(alkylenes oxides) include monomethoxy-polyethylene glycol polypropylene glycol, block copolymers of polyethylene glycol, and polypropylene glycol and the like. The polymers can also be distally capped with
20 C1-4 alkyls instead of monomethoxy groups. The poly(alkylene oxides) used must be soluble in liquid at room temperature. Thus, they preferably have a molecular weight from about 200 to about 20,000 daltons, more preferably about 2,000 to about 10,000 and still more preferably about
25 5,000.

One can administer these stabilized compounds to individuals by a variety of means. For example, these compounds can be included in vaginal foams or gels that are used as preventives to avoid infection and applied before
30 people have sexual contact.

The peptides when used for administration are prepared under aseptic conditions with a pharmaceutically acceptable

carrier or diluent.

Doses of the pharmaceutical compositions will vary depending upon the subject and upon the particular route of administration used. Dosages can range from 0.1 to

5 100,000 μ g/kg a day, more preferably 1 to 10,000 μ g/kg.

Routes of administration include oral, parenteral, rectal, intravaginal, topical, nasal, ophthalmic, direct injection, etc.

Changes in the viral envelope glycoproteins, in particular in the third variable (V3) region of the gp120 exterior envelope glycoprotein, determine tropism-related phenotypes (Cheng-Mayer et al., 1990; O'Brien et al., 1990; Hwang et al., Westervelt et al., 1992; Chesebro et al., 1992; Willey et al., 1994). Amino acid changes in the V3 region (Helseth et al., 1990; Freed et al., 1991; Ivanoff et al., 1991; Bergeron et al., 1992; Grimailla et al., 1992; Page et al., 1992; Travis et al., 1992) and the binding of antibodies to this domain (Putney et al., 1986; Goudsmit et al., 1988; Linsley et al., 1988; Rusche et al., 1988; Skinner et al., Javeherian et al., 1989) have been shown to disrupt a virus entry process other than CD4 binding. Accordingly, one can create derivatives and change the phenotype for a particular receptor by substituting V3 loops.

One can inhibit infection by directly blocking CCR3 and/or CCR5. This can be accomplished by a range of different approaches. For example, antibodies, decoys, small molecules, antagonists, etc. One preferred approach is the use of antibodies to the binding site for these chemokine receptors. Antibodies to these receptors can be prepared by standard means using the gp120 derivatives and gp120/CD4 complexes. For example, one can use single chain

antibodies to target these binding sites. An alternative strategy is to use the stabilized gp120/CD4 complexes as decoys.

As used herein the inhibition of HIV infection means
5 that as compared to a control situation infection is reduced, inhibited or prevented. Infection is preferably at least 20% less, more preferably at least 40% less, even more preferably at least 50% less, still more preferably at least 75% less, even more preferably at least 80% less, and yet
10 more preferably at least 90% less than the control.

The isolated nucleotide sequences and isolated polypeptides of the invention encoding receptors can be mutagenized by any of several standard methods including treatment with hydroxylamine, passage through mutagenic
15 bacterial strains, etc. The mutagenized sequences can then be classified "wild type" or "non-wild type" depending whether it will still facilitate infectivity or not.

Mutagenized sequences can contain point mutations, deletions, substitutions, rearrangements etc. Mutagenized
20 sequences can be used to define the cellular function of different regions of the receptors they encode, and to define the portions of the receptor that facilitate HIV-1 infection. This information can be used to assist in the design of small molecules or peptides mimicking the HIV-
25 interactive part of the chemokine receptor. These small molecule/peptides can be used to inhibit HIV-1 infection. As used herein the inhibition of HIV-infection means that as compared to a control situation infection is reduced, inhibited or prevented. Infection is at least 20% less,
30 preferably at least 40% less, more preferably at least 50% less, still more preferably at least 75% less, even more preferably at least 80% less, and yet more preferably at

least 90% less than the control.

Another approach is to use small molecules that will selectively bind to one of the receptors. Some preferred small molecules include the chemokines themselves (e.g.

5 eotaxin, RANTES, MCP-1, MIP-1 α and/or MIP-1 β), fragments of chemokines, preferably surface fragments, and smaller molecules or peptides that mimic the chemokines. Such molecules and peptides can be synthesized by known techniques.

10 We have also discovered certain coreceptors involved in the binding of another primate immunodeficiency virus--SIV. While SIV have been shown to use CCR5 as a coreceptor, other receptors for the virus have not previously been reported. We have found that two orphan seven-transmembrane segment
15 receptors, gpr1 and gpr15, serve as coreceptors for SIV, and are expressed in alveolar macrophages. gpr15 which is also expressed in CD4⁺ T lymphocytes is the more efficient.

The SIV coreceptors, gpr1 and gpr15, are expressed in U87 and CEMx174 cells, respectively. CEMx174 supports SIV
20 entry but lacks CCR5 and does not support efficient entry of HIV-1 viruses using CCR5. The neuroglioma cell line U87, stably transfected with CD4 similarly supports entry of SIV_{mac} 239 but does not allow for efficient entry of known HIV-1 viruses. We further found that the HIV-1 strains ADA
25 and YU2 weakly use gpr15. This may be an inadvertent consequence of similarities in the amino-terminal regions of gpr15 and CCR5, or it may indicate an adaptation to these or a related receptor that occurs in some HIV-1 subsets.

In primary structure, gpr1 and gpr15 resemble the
30 angiotensin II receptor and the orphan receptors dez and apj more than they do any of the known chemokine receptors [Marchese, A., et al., *Genomics* 23:609-618 (1994); Heiber,

M., et al., *Genomics* 32:462-465 (1996)]. Gpr15, like dez and gpr1, lacks the cysteines in the amino-terminal region and the third extracellular loop that, in the chemokine receptors, are thought to be disulfide linked. It is
5 interesting that, despite the general sequence divergence of gpr15/gpr1 and other identified primate immunodeficiency virus coreceptors, the gpr15 and gpr1 amino termini contain three tyrosines that align with similarly-positioned tyrosines in CCR5 (See Figure 15). Alteration of these
10 tyrosines has been shown to decrease the efficiency with which CCR5 supports the entry of SIV and macrophage-tropic HIV-1 isolates (M. Farzan, H. Choe and J. Sodroski, unpublished observations). The identification of gpr 15 and gpr1 as SIV coreceptors suggests a greater range and
15 complexity of coreceptors for the primate immunodeficiency viruses than heretofore described. Comparative studies of these divergent coreceptors with the known coreceptors for these viruses should assist the identification of common structural elements in 7-TMS proteins that serve as viral
20 entry cofactors.

A molecule that binds to at least one of the tyrosine residues present in the amino terminus of the coreceptors is a preferred molecule for interfering with HIV entry. One class of molecules are antibodies, for example a single
25 chain antibody. One can use a segment of the receptor containing at least one of the tyrosine residues to generate the antibody. For example, one can use fragments of SEQ ID NOS: 1-4 that are at least 6 amino acid residues in length and contain at least one of the conserved tyrosine residues,
30 preferably at least two of the tyrosines residues and more preferably all three conserved tyrosine residues. For example, one could use SEQ ID NO:4 or fragments thereof to

generate an antibody by standard means. Thereafter using the binding assay described herein one can select those antibodies generated that most effectively inhibit chemokine binding such as CCR5 binding. Another class of molecules is
5 a small molecule.

One preferred use of these compounds is to minimize the risk of HIV transmission. These compounds can be included in ointments, foams, creams that can be used during sex. For example, they can be administered preferably prior to or
10 just after sexual contact such as intercourse. One preferred composition would be a vaginal foam containing one of the compounds. Preferably the compound would be a decoy or blocker, for example, a small molecule that binds to the CCR3 receptor. Another use would be in systemic
15 administration to block HIV-1 replication in the blood and tissues. The compound could also be administered in combination with other HIV treatments.

Another strategy is to express antibodies to these receptors in infected individuals intracellularly. This can
20 be done by the method of Marasco and Haseltine set forth in WO94-02610 (PCT/US93/06735 filed July 16, 1993) published February 3, 1994.

In addition, additional compounds that bind to these receptors and thus interfere with their ability to
25 facilitate HIV infection can readily be screened for. For example, one can select cells expressing high numbers of these receptors, plate them; e.g. add labeled gp120 and CD4 and screen for compounds or combinations of compounds that will interact with, e.g. binding of, these receptors by
30 standard techniques. Alternatively, one can use known techniques to prepare cells that will express these receptors and use those cells in drug screens. In

particular, the ability of drugs to block HIV-1 infection or syncytium formation can be screened using assays similar to those showing in Figures 1-5.

One can prepare a drug screen using a cell line or cell
5 membrane expressing CD4 and either CCR3 or CCR5.
Preferably, the surface receptors would only be CD4 and
either CCR3 and/or CCR5. In another embodiment one would
use a cell line or cell membrane that expresses CD4 and the
only other chemokine co-receptor would be CCR3 and/or CCR5.
10 Thus, one can determine if the compounds tested affect
infectivity by HIV-1. Such a method can be used to select
molecules that specifically affect the pathway. These
molecules may be combined with other drugs, for example, for
their combined or synergistic effects. In contrast, when
15 comparing CD4 cells there can be a variety of other factors
affecting such cells, thus, such a comparison does not
provide the same data.

One can also prepare cell lines stably expressing CCR3
or CCR5, by themselves, or with CD4. Such cells can be used
20 for a variety of purposes including an excellent source of
antigen for preparing a range of antibodies using techniques
well known in the art.

By creating cells expressing these receptors, one can
enhance the range of cells these primary HIV-1 macrophage
25 tropic strains can infect. For example, one can use CD4
expressing cell lines or vector systems cotransfecting the
genes encoding CD4 and at least one of these receptors.

One of the problems that has been encountered in in
vivo testing compounds that affect HIV-1 is the relatively
30 small number of animals that can be infected by HIV. While
systems such as a chimeric virus comprising SIV and HIV
(SHIV) have extended the number of animal models that can be

used, this approach is primarily directed to systems that use other primates. Now one can prepare transgenic animals that have cells that express CD4 and at least CCR5 or CCR3 to further extend the range of animals susceptible to HIV-1 infection. This permits one to create a much broader range of animal models.

A "transgenic animal" is an animal having cells that contain DNA which has been artificially inserted into a cell, which DNA becomes part of the genome of the somatic cells and/or the germ line of the animal that develops from that cell. The preferred DNA contains nucleotide sequences that are homologous to human CD4, CCR3 and/or CCR5 genes. These sequences may be entirely foreign to the transgenic animal or may even be identical to the homologous gene of the animal, but which is inserted into the animal's genome at a location which differs from that of the natural copy. Transgenic animals can provide good model systems for studying the development of AIDS, the effects of potential therapeutic reagents, and the safety (e.g. toxicity, carcinogenicity) of such agents administered to the animals.

Therapeutic and Pharmaceutical Compositions

An exemplary pharmaceutical composition is a therapeutically effective amount of a decoy, antibody etc. that affects the ability of the receptor to facilitate HIV infection optionally included in a pharmaceutically-acceptable and compatible carrier. The term "pharmaceutically-acceptable and compatible carrier" as used herein, and described more fully below, includes (i) one or more compatible solid or liquid filler diluents or encapsulating substances that are suitable for administration to a human or other animal, and/or (ii) a

system, such as a retroviral vector, capable of delivering the molecule to a target cell. In the present invention, the term "carrier" thus denotes an organic or inorganic ingredient, natural or synthetic, with which the molecules of the invention are combined to facilitate application. The term "therapeutically-effective amount" is that amount of the present pharmaceutical compositions which produces a desired result or exerts a desired influence on the particular condition being treated. Various concentrations may be used in preparing compositions incorporating the same ingredient to provide for variations in the age of the patient to be treated, the severity of the condition, the duration of the treatment and the mode of administration.

The term "compatible", as used herein, means that the components of the pharmaceutical compositions are capable of being commingled with a small molecule, nucleic acid and/or polypeptides of the present invention, and with each other, in a manner such that does not substantially impair the desired pharmaceutical efficacy.

Dose of the pharmaceutical compositions of the invention will vary depending on the subject and upon particular route of administration used. Dosages can range from 0.1 to 100,000 $\mu\text{g}/\text{kg}$ per day, more preferably 1 to 10,000 $\mu\text{g}/\text{kg}$. By way of an example only, an overall dose range of from about, for example, 1 microgram to about 300 micrograms might be used for human use. This dose can be delivered at periodic intervals based upon the composition.

For example on at least two separate occasions, preferably spaced apart by about 4 weeks. Other compounds might be administered daily. Pharmaceutical compositions of the present invention can also be administered to a subject according to a variety of other, well-characterized

protocols. For example, certain currently accepted immunization regimens can include the following: (i) administration times are a first dose at elected date; a second dose at 1 month after first dose; and a third dose at 5 months after second dose. See Product Information, *Physician's Desk Reference*, Merck Sharp & Dohme (1990), at 1442-43. (e.g., Hepatitis B Vaccine-type protocol); (ii) Recommended administration for children is first dose at elected date (at age 6 weeks old or older); a second dose at 4-8 weeks after first dose; a third dose at 4-8 weeks after second dose; a fourth dose at 6-12 months after third dose; a fifth dose at age 4-6 years old; and additional boosters every 10 years after last dose. See Product Information, *Physician's Desk Reference*, Merck Sharp & Dohme (1990), at 879 (e.g., Diphtheria, Tetanus and Pertussis-type vaccine protocols). Desired time intervals for delivery of multiple doses of a particular composition can be determined by one of ordinary skill in the art employing no more than routine experimentation.

The small molecules and polypeptides of the invention may also be administered *per se* (neat) or in the form of a pharmaceutically acceptable salt. When used in medicine, the salts should be pharmaceutically acceptable, but non-pharmaceutically acceptable salts may conveniently be used to prepare pharmaceutically acceptable salts thereof and are not excluded from the scope of this invention. Such pharmaceutically acceptable salts include, but are not limited to, those prepared from the following acids: hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, maleic, acetic, salicylic, p-toluene-sulfonic, tartaric, citric, methanesulphonic, formic, malonic, succinic, naphthalene-2-sulfonic, and benzenesulphonic. Also,

pharmaceutically acceptable salts can be prepared as alkaline metal or alkaline earth salts, such as sodium, potassium or calcium salts of the carboxylic acid group. Thus, the present invention also provides pharmaceutical compositions, for medical use, which comprise nucleic acid and/or polypeptides of the invention together with one or more pharmaceutically acceptable carriers thereof and optionally any other therapeutic ingredients.

The compositions include those suitable for oral, rectal, intravaginal, topical, nasal, ophthalmic or parenteral administration, all of which may be used as routes of administration using the materials of the present invention. Other suitable routes of administration include intrathecal administration directly into spinal fluid (CSF), direct injection onto an arterial surface and intraparenchymal injection directly into targeted areas of an organ. Compositions suitable for parenteral administration are preferred. The term "parenteral" includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques.

The compositions may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Methods typically include the step of bringing the active ingredients of the invention into association with a carrier which constitutes one or more accessory ingredients.

Compositions of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets, tablets or lozenges, each containing a predetermined amount of the nucleic acid and/or polypeptide of the invention in liposomes or as a suspension in an

aqueous liquor or non-aqueous liquid such as a syrup, an elixir, or an emulsion.

Preferred compositions suitable for parenteral administration conveniently comprise a sterile aqueous preparation of the molecule of the invention which is preferably isotonic with the blood of the recipient. This aqueous preparation may be formulated according to known methods using those suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectibles.

Antibodies

The term "antibodies" is meant to include monoclonal antibodies, polyclonal antibodies and antibodies prepared by recombinant nucleic acid techniques that are selectively reactive with polypeptides encoded by eukaryotic nucleotide sequences of the present invention. The term "selectively reactive" refers to those antibodies that react with one or more antigenic determinants of CCR3 or CCR5, or gp120 and/or CD4 and do not react with other polypeptides. Antigenic determinants usually consist of chemically active surface groupings of molecules such as amino acids or sugar side

chains and have specific three dimensional structural characteristics as well as specific charge characteristics. Antibodies can be used for diagnostic applications or for research purposes.

5 For example, antibodies may be raised against amino-terminal (N-terminal) or carboxyl-terminal (C-terminal) peptides of a polypeptide encoded by CCR3, CCR5. Most preferably one selects an exposed cell-surface epitope of one of these receptors.

10 One approach is to isolate a peptide sequence that contains an antigenic determinant for use as an immunogen. This peptide immunogen can be attached to a carrier to enhance the immunogenic response. Although the peptide immunogen can correspond to any portion of a polypeptide
15 encoded by a eukaryotic nucleotide sequence of the invention, certain amino acid sequences are more likely than others to provoke an immediate response, for example, an amino acid sequence including the N- or C-terminus of a polypeptide encoded by a gene that contains nucleotide
20 sequences of the invention. Preferably one can use a cell line expressing only CCR3, select those cells with the highest levels of expression and use the whole cell as an antigen.

25 For example, cDNA clone encoding a CCR3, CCR5 or a fragment thereof may be expressed in a host using standard techniques (see above; see Sambrook et al., Molecular Cloning; A Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, New York: 1989) such that 5-20% of the total protein that can be recovered from the host is the desired
30 protein. Recovered proteins can be electrophoresed using PAGE and the appropriate protein band can be cut out of the gel. The desired protein sample can then be eluted from the

gel slice and prepared for immunization. Alternatively, a protein of interest can be purified by using conventional methods such as, for example, ion exchange hydrophobic, size exclusion, or affinity chromatography.

5 Once the protein immunogen is prepared, mice can be immunized twice intraperitoneally with approximately 50 micrograms of protein immunogen per mouse. Sera from such immunized mice can be tested for antibody activity by immunohistology or immunocytology on any host system
10 expressing such polypeptide and by ELISA with the expressed polypeptide. For immunohistology, active antibodies of the present invention can be identified using a biotin-conjugated anti-mouse immunoglobulin followed by avidin-peroxidase and a chromogenic peroxidase substrate.
15 Preparations of such reagents are commercially available; for example, from Zymad Corp., San Francisco, California. Mice whose sera contain detectable active antibodies according to the invention can be sacrificed three days later and their spleens removed for fusion and hybridoma
20 production. Positive supernatants of such hybridomas can be identified using the assays described above and by, for example, Western blot analysis.

 To further improve the likelihood of producing an antibody as provided by the invention, the amino acid
25 sequence of polypeptides encoded by a eukaryotic nucleotide sequence of the present invention may be analyzed in order to identify portions of amino acid sequence which may be associated with increased immunogenicity. For example, polypeptide sequences may be subjected to computer analysis
30 to identify potentially immunogenic surface epitopes. Such computer analysis can include generating plots of antigenic index, hydrophilicity, structural features such as

amphophilic helices or amphophilic sheets and the like.

For preparation of monoclonal antibodies directed toward polypeptides encoded by a eukaryotic nucleotide sequence of the invention, any technique that provides for the production of antibody molecules by continuous cell lines may be used. For example, the hybridoma technique originally developed by Kohler and Milstein (Nature, 256: 495-497, 1973), as well as the trioma technique, the human B-cell hybridoma technique (Kozbor et al., Immunology Today, 4:72), and the EBV-hybridoma technique to produce human monoclonal antibodies, and the like, are within the scope of the present invention. See, generally Larrick et al., U.S. Patent 5,001,065 and references cited therein. Further, single-chain antibody (SCA) methods are also available to produce antibodies against polypeptides encoded by a eukaryotic nucleotide sequence of the invention (Ladner et al. U.S. patents 4,704,694 and 4,976,778).

The monoclonal antibodies may be human monoclonal antibodies or chimeric human-mouse (or other species) monoclonal antibodies. The present invention provides for antibody molecules as well as fragments of such antibody molecules.

Those of ordinary skill in the art will recognize that a large variety of possible moieties can be coupled to the resultant antibodies or to other molecules of the invention. See, for example, "Conjugate Vaccines", Contributions to Microbiology and Immunology, J.M. Cruse and R.E. Lewis, Jr (eds), Carger Press, New York, (1989), the entire contents of which are incorporated herein by reference.

Coupling may be accomplished by any chemical reaction that will bind the two molecules so long as the antibody and the other moiety retain their respective activities. This

linkage can include many chemical mechanisms, for instance covalent binding, affinity binding, intercalation, coordinate binding and complexation. The preferred binding is, however, covalent binding. Covalent binding can be achieved either by direct condensation of existing side chains or by the incorporation of external bridging molecules. Many bivalent or polyvalent linking agents are useful in coupling protein molecules, such as the antibodies of the present invention, to other molecules. For example, representative coupling agents can include organic compounds such as thioesters, carbodiimides, succinimide esters, diisocyanates, glutaraldehydes, diazobenzenes and hexamethylene diamines. This listing is not intended to be exhaustive of the various classes of coupling agents known in the art but, rather, is exemplary of the more common coupling agents. (See Killen and Lindstrom 1984, "Specific killing of lymphocytes that cause experimental Autoimmune Myasthenia Gravis by toxin-acetylcholine receptor conjugates." Jour. Immun. 133:1335-2549; Jansen, F.K., H.E. Blythman, D. Carriere, P. Casella, O. Gros, P. Gros, J.C. Laurent, F. Paolucci, B. Pau, P. Poncelet, G. Richer, H. Vidal, and G.A. Voisin. 1982. "Immunotoxins: Hybrid molecules combining high specificity and potent cytotoxicity" . Immunological Reviews 62:185-216; and Vitetta et al., supra).

Preferred linkers are described in the literature. See, for example, Ramakrishnan, S. et al., Cancer Res. 44:201-208 (1984) describing use of MBS (M-maleimidobenzoyl-N-hydroxysuccinimide ester). See also, Umemoto et al. U.S. Patent 5,030,719, describing use of halogenated acetyl hydrazide derivative coupled to an antibody by way of an oligopeptide linker. Particularly preferred linkers

include: (i) EDC (1-ethyl-3-(3-dimethylamino-propyl) carbodiimide hydrochloride; (ii) SMPT (4-succinimidylloxycarbonyl-alpha-methyl-alpha-(2-pyridyl-dithio)-toluene (Pierce Chem. Co., Cat. (21558G); (iii) SPDP (succinimidyl-6 [3-(2-pyridyldithio) propionamido] hexanoate (Pierce Chem. Co., Cat #21651G); (iv) Sulfo-LC-SPDP (sulfosuccinimidyl 6 [3-(2-pyridyldithio)-propionamide] hexanoate (Pierce Chem. Co. Cat. #2165-G); and (v) sulfo-NHS (N-hydroxysulfo-succinimide: Pierce Chem. Co., Cat. #24510) conjugated to EDC.

The linkers described above contain components that have different attributes, thus leading to conjugates with differing physio-chemical properties. For example, sulfo-NHS esters of alkyl carboxylates are more stable than sulfo-NHS esters of aromatic carboxylates. NHS-ester containing linkers are less soluble than sulfo-NHS esters. Further, the linker SMPT contains a sterically hindered disulfide bond, and can form conjugates with increased stability. Disulfide linkages, are in general, less stable than other linkages because the disulfide linkage is cleaved in vitro, resulting in less conjugate available. Sulfo-NHS, in particular, can enhance the stability of carbodimide couplings. Carbodimide couplings (such as EDC) when used in conjunction with sulfo-NHS, forms esters that are more resistant to hydrolysis than the carbodimide coupling reaction alone.

Antibodies of the present invention can be detected by appropriate assays, e.g., conventional types of immunoassays. For example, a sandwich assay can be performed in which the receptor or fragment thereof is affixed to a solid phase. Incubation is maintained for a sufficient period of time to allow the antibody in the

sample to bind to the immobilized polypeptide on the solid phase. After this first incubation, the solid phase is separated from the sample. The solid phase is washed to remove unbound materials and interfering substances such as non-specific proteins which may also be present in the sample. The solid phase containing the antibody of interest bound to the immobilized polypeptide of the present invention is subsequently incubated with labeled antibody or antibody bound to a coupling agent such as biotin or avidin. Labels for antibodies are well-known in the art and include radionuclides, enzymes (e.g. maleate dehydrogenase, horseradish peroxidase, glucose oxidase, catalase), fluors (fluorescein isothiocyanate, rhodamine, phycocyanin, fluorescamine), biotin, and the like. The labeled antibodies are incubated with the solid and the label bound to the solid phase is measured, the amount of the label detected serving as a measure of the amount of anti-urea transporter antibody present in the sample. These and other immunoassays can be easily performed by those of ordinary skill in the art.

The following Examples serve to illustrate the present invention, and are not intended to limit the invention in any manner.

25

EXAMPLES

Plasmids

The pHXBH10 Δ envCAT and pSVIIIenv plasmids used to produce recombinant HIV-1 virions have been previously described (Helseth et al., 1990; Thali et al., 1994). The pCD4 plasmid expressing full-length human CD4 has been described (Brand et al., 1995). The SV-A-MLF-Env plasmid expressing the amphotropic murine leukemia virus envelope

glycoproteins was obtained from Dan Littman (Landau et al., 1991). The derivation and construction of the pSVIIIenv plasmids expressing the envelope glycoproteins from various strains of HIV-1 have been described (Sullivan et al., 1995; 5 Gao et al., 1996; Karlsson et al., 1996). The chimeric HXBc2 (YU2-V3) and HXBc2 (ADA-V3) env constructs were kindly supplied by Lee Ratner, and were designated HY (V3A + V3B) and HA (V3A + V3B) in a previous publication (Carrillo et al., 1993). The chimeric HXBc2 (YU2-V1/V2) env genes were 10 created by substituting the Dra III Stu I fragment of the YU2 env gene into the corresponding segment (nucleotides 6619 to 6901) of the HXBc2 env gene. The cDNAs encoding the chemokine receptors were cloned into the pcDNA3 vector (Invitrogen) for expression. The CCR1, CCR3 and CCR5 15 proteins, which are known sequences, were also expressed as fusion proteins containing an epitope tag (MDYKDDDDK) (SEQ ID NO:5) (FLAG tag, IBI-Kodak) at the amino terminus.

Cell lines

20 HeLa cells were grown in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum and antibiotics. HeLa-CD4 (clone 1022) cells were obtained from Dr. Bruce Chesebro through the National Institutes of Health AIDS Research and Reference Reagent Program. The Cf2Th canine 25 thymocyte line was obtained from the American Type Culture Collection (ATCC CRL 1430) and was propagated in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum.

Env-complementation Assay

30 HeLa cells were cotransfected by the calcium phosphate method (Cullen, 1989) either with 15 μ g pHXBH10 Δ envCAT alone or with 15 μ g pHXBH10 Δ envCAT and 3 μ g pSVIIIenv or SV-

A-MLV-Env to produce recombinant virions, as previously described (Thali et al., 1994; Karlsson et al., 1996). HeLa cells to be used as target cells were plated at 7×10^5 cells per 100 mm dish, cultured overnight, and then

5 transfected by the calcium phosphate method Mg pCDNA3 expressing chemokine receptors. Control HeLa cells were transfected with 10 Mg pCD4 and 25 with 10 μ g pCD4 and 25 μ g pCDM8 expressing the CD2 protein, which has been shown to have no effect on HIV-1 infection (H.-R. Choe and J.

10 Sodroski, unpublished observations). The pCDM8 plasmid expressing CD2 was a gift from Dr. Ellis Reinherz. Sixty hours following transfection, the HeLa target cells were detached from the tissue culture dish by treatment with phosphate-buffered saline and 5mM EDTA. The cell suspension

15 was diluted in medium, with one aliquot used for FACS analysis and the remaining aliquots replated into 6-well plates for infection. The level of CD4 expressed on the cell surface was measured by flow cytometry, using the FITC-conjugated OKT4 antibody reactive with CD4 domain 3

20 (McDougal et al., 1986). Approximately six hours after replanting, cells were infected by incubation with recombinant virions (20,000 cpm of reverse transcriptase activity) in 1 ml of medium. After overnight incubation at 37°C, additional medium was added to the cells. After a

25 total of approximately 60 hours of incubation of the virus-cell mixture at 37°C, the cells were lysed and used for determination of CAT activity.

For some of the experiments, the level of chemokine receptor expression on the transfected HeLa cells was

30 measured by FACS analysis 60 hours following transfection. The antibody (anti-FLAG M2, Kodak) against the epitope tag (FLAG tag) was used for analysis of CCR1, CCR3 and CCR5

expression. Monoclonal antibodies were used to detect surface expression of CCR2, IL8R-A and IL8R-B, respectively.

In some of the experiments, Cf2Th canine thymocytes were used as target cells. The Cf2Th cells were transfected by the calcium phosphate technique with 10 μ g of the pCD4 plasmid and 25 μ g of the pCDNA3 plasmid expressing chemokine receptors or, as a control, with 10 μ g of the pCD4 plasmid and 25 μ g of the pCDM8 plasmid expressing CD2 (see above). Approximately 72 hours after transfection, the Cf2Th cells were incubated with recombinant HIV-1 and used for measurement of CAT as described above.

Eotaxin Inhibition of HIV-1 Infectivity

Recombinant HIV-1 containing the YU2 and A-MuLV envelope glycoproteins were produced in HeLa cells as described above. HeLa-CD4 (clone 1022) cells, transfected either with the pCDM8 plasmid expressing CD2 or with the pCDNA3 plasmid expressing chemokine receptors, were used as target cells. The target cells, in 1 ml medium, were incubated with different concentrations (0-60 nM) of eotaxin (Jose et al., 1994; Ponath et al., 1996a and which is commercially available) for 90 minutes at 37°C. Medium was then removed and the cells were resuspended in 1 ml medium containing recombinant virus (15,000 reverse transcriptase units). Eotaxin was added to the virus-cell mixture at the original concentration. After 12 hours at 37°C, the cells were washed and returned to the incubator. After an additional 60 hours at 37°C, the cells were lysed and used for measurement of CAT activity.

Syncytium Formation Assay

Envelope glycoprotein-expressing HeLa cells were

derived by transfection of HeLa cells with pSVIIIenv plasmids expressing HIV-1 envelope glycoproteins (Helseth et al., 1990). Target cells were derived by transfection of HeLa-CD4 (clone 1022) cells with plasmids expressing either CCR1, CCR3 or CCR5. Forty-eight hours after transfection, the envelope glycoprotein expressing and target HeLa cells were detached from the tissue culture plates using 5 mM EDTA. Cells were replated at a ratio of ten target cells to one envelope glycoprotein-expressing cell, and incubated at 37°C in 5% CO₂. Twelve hours later, the number of syncytia in the wells were counted. Control experiments were performed in which 2 µg/ml OKT4a (Ortho Pharmaceuticals, Inc.) was included at the time of replating. An additional control using the pCEP4 plasmid (Invitrogen), which does not express any envelope glycoproteins, was performed to assess background levels of syncytia.

RESULTS

Some Chemokine Receptors Facilitate Infection by Macrophage-tropic HIV-1.

To assess the efficiency with which HIV-1 viruses containing different envelope glycoproteins mediate early events in HIV-1 infection, an env-complementation assay (Helseth et al., 1990; Thali et al., 1994) was utilized. Recombinant HIV-1 viruses were produced by cotransfection of HeLa cells with two plasmids, pHXBH10ΔenvCAT and pSVIIIenv. The pHXBH10ΔenvCAT plasmid contains an HIV-1 provirus with a deletion in the env gene and a replacement of the nef gene with a gene encoding chloramphenicol acetyltransferase (CAT). Different pSVIIIenv plasmids encoding the envelope glycoproteins derived from a laboratory-adapted HIV-1 isolate (HXBc2) and from macrophage-tropic primary HIV-1

isolates (Br20-4, ADA and YU2) were used. The recombinant viruses produced in the HeLa supernatants thus contain different envelope glycoproteins, allowing an assessment of the ability of these glycoproteins to mediate a single round of infection. Control viruses lacking envelope glycoproteins were produced by transfecting HeLa cells with the pHXBH10 Δ envCAT plasmid alone. An equal number of reverse transcriptase units of the recombinant viruses in the HeLa supernatants was incubated with target cells. HeLa cells transfected with plasmids expressing human CD4 and various seven-transmembrane-segment receptors were used as target cells. The efficiency of the early phase of virus infection was assessed by measurement of CAT activity in the HeLa target cells 60 hours following infection.

Expression of human CD4 in HeLa cells was sufficient for efficient infection of these cells by a recombinant virus containing the laboratory-adapted HXBc2 envelope glycoproteins, as previously published (Brand et al., 1995) (Figure 1 and Table 1). By contrast, infection of HeLa cells expressing CD4 by viruses with the macrophage-tropic ADA, YU2 and Br20-4 envelope glycoproteins was inefficient.

Other studies have demonstrated that recombinant viruses with these envelope glycoproteins are able to infect human PBMC (Westervelt et al., 1991; Sullivan et al., 1995; Karlson et al., 1996). These results are consistent with previous observations suggesting that macrophage-tropic primary HIV-1 isolates enter most immortalized cells inefficiently (Cheng-Mayer et al., 1988; Schuitemaker et al., 1991; Chesbro et al., 1991).

Plasmids expressing the cDNAs of a number of chemokine receptors and related molecules were cotransfected with the CD4-expressing plasmid into the HeLa cells. The level of

CD4 expression on the surface of the HeLa cells was not affected by coexpression of the chemokine receptors examined (data not shown). As shown in Table 1, the expression of most of the seven-transmembrane receptors did not affect
5 infection by the recombinant HIV-1 viruses. Expression of the CCR5 molecule resulted in significant enhancement of infection by viruses with the ADA, YU2 and Br20-4 envelope glycoproteins, but had no effect on infection by the virus containing the HXBc2 envelope glycoproteins (Figure 1 and
10 Table 1). Expression of the CCR3 molecule also resulted in enhanced infection by the viruses with ADA and YU2 envelope glycoproteins. The magnitude of this effect (9-32-fold) was smaller than that seen for CCR5 (35-45 fold). CCR3 did not stimulate infection by the viruses with BR20-4 and HXBc2
15 envelope glycoproteins. The enhancing effects of CCR3 and CCR5 expression were not seen when human CD4 was not expressed in the HeLa target cells (Table 1).

To examine whether the level of expression of the chemokine receptors on the surface of the transfected HeLa
20 cells might have influenced the results, FACS analysis was used to verify the expression of a subset of the chemokine receptors (Table 1 legend). Although specific reagents for examining wild-type CCR5 expression were not available, FACS analysis with a CCR3-directed monoclonal antibody revealed
25 that cell surface expression of the wild-type CCR3 protein was inefficient (data not shown). This is consistent with previous attempts to express CCR3 in the context of a heterologous cell (Daugherty et al., 1996; Ponath et al., 1996; Ponath et al., 1996b). To compare cell surface
30 expression of CCR1, CCR3 and CCR5 directly, the CCR1F, CCR3F and CCR5F proteins, which have identical amino-terminal epitope tags (Kunz et al., 1992), were studied. The

presence of the epitope tag on the CCR3F and CCR5F molecules only minimally affected the observed enhancement of infection by the primary viruses (Table 1). Cell surface levels of CCR1F and CCR5F were approximately 83- and 24-fold lower, respectively, than that of CCR1F in the transfected HeLa cells, when background fluorescence was taken into account (Table 1 legend). Thus, the enhancement of primary virus infection by CCR3 and CCR5 appears to be specific, and is not merely a result of higher surface expression of these receptors.

We wished to examine whether increasing the cell surface level of CCR3 and CCR5 might increase the magnitude of the observed enhancement of infection. Prior to virus infection, transfected HeLa cells were incubated with sodium butyrate, which has been shown to enhance the transcriptional activity of the cytomegalovirus immediate early promoter used for chemokine receptor expression on the pcDNA3 plasmid (Palermo et al., 1991). FACS analysis indicated that sodium butyrate treatment increased the surface level of both CCR1F and CCR3F expression by approximately 1.5-fold (data not shown). An increase in the level of infection by the virus with the YU2 envelope glycoproteins resulted, whereas sodium butyrate treatment had no effect on infection by a control recombinant virus containing the amphotropic murine leukemia virus (A-MuLV) envelope glycoproteins (Table 1 and data not shown). Sodium butyrate treatment of HeLa cells transfected with plasmids expressing CD4 and CCR1F did not affect infection by the YU2 recombinant virus. The results indicate that the cell surface levels of CCR3 and CCR5 expression are limiting the magnitude of the observed enhancement of infection by viruses with primary, macrophage-tropic envelope

glycoproteins.

Infection by Diverse HIV-1 is Enhanced by CCR5

All of the envelope glycoproteins used in the
5 experiments described above were derived from HIV-1 viruses
from phylogenetic clade B (Myers et al., 1994). To examine
the generality of the observed enhancement, HeLa cells
transiently expressing CD4 and either CD2, CCR3 or CCR5 were
incubated with recombinant viruses containing envelope
10 glycoproteins from a geographically diverse set of primary
HIV-1 isolates (Gao et al., 1996; Karlsson et al., 1996).
CCR1F was also expressed as a control in these experiments.
The results, shown in Table 2, indicate that CCR5 was able
to enhance the infection of a broader array of viruses than
15 was CCR3. The infection of all of the primary viruses than
was CCR3. The infection of all the primary viruses was
increased in cells expressing CD4 and CCR5 relative to that
seen in cells expressing CD4 and CD2 or CD4 and CCR1F. Of
the panel of viruses tested, only those containing the ADA
20 and YU2 envelope glycoproteins infected HeLa cells
expressing CD4 and CCR3 more efficiently than HeLa cells
expressing CD4 and CD2. Recombinant viruses containing
laboratory-adapted (HXBc2) viral envelope glycoproteins did
not infect HeLa cells expressing either CCR3 or CCR5 more
25 efficiently than they infected control cells expressing CD4
and CD2 or CD4 and CCR1F. Infection by control HIV-1
viruses pseudotyped with the amphotropic murine leukemia
virus (A-MuLV) envelope glycoproteins (Landau et al., 1991)
was not increased by the expression of CCR3 and CCR5 on the
30 target cells.

Inhibition of CCR3-dependent HIV-1 Infection by Eotaxin

It has been reported that RANTES, MIP-1 α , and MIP-1 β , the ligands for CCR5, inhibit the infection of primary HIV-1 isolates (Cocchi et al., 1995; Paxton et al., 1996). We wished to examine whether the binding of a ligand to CCR3 would affect the ability of this chemokine receptor to facilitate HIV-1 infection. HeLa-CD4 cells transiently expressing CCR3 were incubated with eotaxin, the major CCR3 ligand (Jose et al., 1994; Ponath et al., 1996a), prior to infection by recombinant viruses containing the YU2 or murine amphotropic envelope glycoproteins. Additional control HeLa-CD4 cells expressing CCR1F, CCR5, or CD2 were included in the assay. The data in Figure 2 indicate that eotaxin exhibited a dose-dependent inhibition of infection of HeLa-CD4 cells expressing CCR3 by YU2 recombinant viruses. No effect of eotaxin was observed, even at high concentrations, on infection by the recombinant viruses with the A-MuLV envelope glycoproteins. No effect of eotaxin was observed on the infection of CCR5-expressing HeLa-CD4 cells by the YU2 recombinant virus. These results indicate that, under circumstances where HIV-1 infection is dependent upon CCR3, eotaxin can inhibit the efficiency of this process.

Chemokine Receptors Facilitate CD-4 Dependent HIV-1 Infection of Non-human Cells

To examine whether CCR3 and CCR5 expression could facilitate HIV-1 infection of a non-human target cell, Cf2Th canine thymocytes were transfected with a plasmid expressing human CD4 in combination with a plasmid expressing either CD2, CCR3 or CCR5. A plasmid expressing HUMSTSR, which has been reported to facilitate membrane fusion by laboratory-adapted HIV-1 isolates (Feng et al., 1996), was also included in this experiment. Since HUMSTSR is expressed at

high levels in HeLa cells (Feng et al., 1996), the use of different target cells allowed an examination of the effect of HUMSTSR expression on infection by the recombinant viruses used in this study. Since most T cell line-tropic primary HIV-1 isolates and laboratory-adapted isolates enter CD4-positive HeLa cells efficiently (Chesebro et al., 1991), the use of the Cf2Th cells also allowed us to assess the effect of chemokine receptor expression on infection by these types of viruses. The results in Figure 3 indicate that none of the recombinant HIV-1 viruses containing the macrophage-tropic primary envelope glycoproteins (ADA, YU2), T cell line-tropic primary envelope glycoproteins (89.6, ELI), or the laboratory-adapted (HXBc2) envelope glycoproteins efficiently infected Cf2Th cells expressing human CD4. Recombinant viruses containing the A-MuLV envelope glycoproteins were able to infect the Cf2Th cells at a high level of efficiency. This was expected since all of the Cf2Th cells in the culture were potentially susceptible to infection by the viruses with A-MuLV envelope glycoproteins. By contrast, only the fraction of cells successfully transfected were potentially infectible by the viruses with HIV-1 envelope glycoproteins. Expression of HUMSTSR in addition to CD4 facilitated infection by the HXBc2 and 89.6 recombinant viruses but did not affect infection by viruses with ADA or YU2 envelope glycoproteins. A small positive effect of HUMSTSR expression was seen on infection by the ELI recombinant virus. These results are consistent with a published report indicating that HUMSTSR expression facilitated cell fusion directed by the envelope glycoproteins of laboratory-adapted HIV-1 but not of macrophage-tropic primary HIV-1 isolates (Feng et al., 1996). The results also demonstrate that HUMSTSR can be

utilized by at least some T cell line-tropic primary envelope glycoproteins to facilitate infection. Coexpression of CCR3 with human CD4 enhanced infection by the ADA and YU2 recombinant viruses, with smaller positive effects seen for the 89.6 and ELI recombinant viruses. CCR3 expression did not affect the efficiency of infection by the virus with the HXBc2 envelope glycoproteins. Infection of the CD4-expressing Cf2Th cells by the ADA, YU2 and 89.6 recombinant viruses, but not by the ELI and HXBc2 recombinant viruses, was enhanced by the coexpression of CCR5. These results suggest that HUMSTSR can be utilized by some T cell line-tropic primary and laboratory-adapted HIV-1 isolates for infection and that CCR3 and CCR5 can be utilized by some T cell line-tropic and macrophage-tropic primary isolates.

HIV-1 Envelope Glycoprotein Determinants of CCR3 and CCR5 Utilization

A major, although not the sole, determinant of viral tropism is the primary structure of the third variable (V3) region of the HIV-1 gp120 glycoprotein (Cheng-Mayer et al., 1990; O'Brien et al., 1990; Hwang et al., 1991; Westervelt et al., 1991; Chesebro et al., 1992; Willey et al., 1994). To examine whether V3 structure influenced sensitivity of HIV-1 to the presence of CCR3 and CCR5 on the target cell surface, HeLa-CD4 cells expressing CCR3 or CCR5 were incubated with viruses containing chimeric gp120 envelope glycoproteins. These chimeric envelope glycoproteins are identical to that of the HXBc2 laboratory-adapted isolate, except that the V3 loop is derived from the ADA and YU2 macrophage-tropic primary isolates (Westervelt et al., 1992; Carrillo et al., 1992). The ADA and YU2 V3 domains have

been shown to confer a chimeric envelope glycoproteins the ability to support infection of primary macrophages (Westervelt 1992.) Table 3 shows that recombinant viruses containing the chimeric glycoproteins with the ADA and YU2 V3 loops, in contrast to those containing the parental HXBc2 envelope glycoproteins, were able to infect HeLa-CD4 cells more efficiently when either CCR3 or CCR5 was expressed on the target cell. Substitution of the YU V1/V2 variable loops into the HXBc2 envelope glycoproteins did not increase the efficiency of infection of HeLa-CD4 target cells expressing CCR3 or CCR5, compared with the cells expressing the CD2 control protein. These results indicate that the structure of the gp120 V3 loop can influence the ability of HIV-1 viruses to respond to the presence of these chemokine receptors in the target cells.

Cell-cell Fusion is Influenced by CCR3 and CCR5

Our results indicate that an envelope glycoprotein-specific process early in the HIV-1 life cycle is influenced by the expression of CCR3 and CCR5 on the target cell. To examine whether the membrane fusion process is enhanced by the presence of these chemokine receptors, we utilized an assay measuring HIV-1 envelope glycoprotein-mediated syncytium formation. In this assay, HeLa cells expressing different HIV-1 envelope glycoproteins were cocultivated with either mock-transfected HeLa-CD4 cells or HeLa-CD4 cells expressing CCR1F, CCR3 or CCR5. Figure 4 shows that the number of syncytia observed when no envelope glycoproteins were expressed in the HeLa cells was minimal. HeLa cells expressing the HXBc2 envelope glycoproteins formed syncytia with HeLa-CD4 cells (data not shown), consistent with the expression of endogenous HUMSTR in this

cell line (Feng et al., 1996). The ADA and YU2 envelope glycoproteins, by contrast, did not mediate the formation of syncytia with the CD4-positive HeLa cells expressing the CCR1 protein. Syncytium formation directed by the chimeric HXBc2 (ADA-V3) and HXBc2 (YU2-V3) envelope glycoproteins was also inefficient with CCR1-expressing HeLa-CD4 target cells. Expression of CCR3 in addition to CD4 on the HeLa cells resulted in syncytium formation directed by the YU2 envelope glycoproteins. The expression of CCR5 on the HeLa-CD4 cells allowed the formation of syncytia with cells expressing the ADA, YU2 and chimeric envelope glycoproteins. The number of syncytia formed by the HXBc2 envelope glycoproteins was not affected by CCR3 or CCR5 expression on the CD4-positive HeLa cells (data not shown). Syncytium formation in this assay was dependent upon gp120 binding to CD4, since the OKT4a anti-CD4 monoclonal antibody, which blocks gp120-CD4 interaction (McDougal et al., 1986), inhibited the formation of syncytia. These results indicate that expression of CCR3 and CCR5 on CD4-positive target cells can enhance fusion events mediated by macrophage-tropic primary virus envelope glycoproteins. The results also indicate that the HIV-1 gp120 V3 loop sequence determines the ability of the envelope glycoproteins to utilize CCR5 as a fusion cofactor.

The results presented herein indicate that, in addition to CD4, members of the chemokine receptor family play critical roles in early events in HIV-1 infection. The particular chemokine receptors utilized by HIV-1 variants differ, depending upon previously characterized differences in target cell preference. The ability of laboratory-adapted HIV-1 viruses to replicate in immortalized CD4-positive cells lines has been shown to involve an orphan receptor CXCR4, previously referred to as fusin, HUMSTR,

LESTR, or LCR1 (Feng et al., 1996). Our results confirm the involvement of HUMSTR in infection by laboratory-adapted HIV-1 and demonstrate a role for this molecule in infection by some primary, T-cell line-tropic HIV-1 isolates. Our results indicate that the clinically-relevant, macrophage-tropic HIV-1 can use other members of the chemokine receptor family, such as CCR3 and CCR5, to facilitate infection.

Although the tissue and cell-type distribution of CCR3 and CCR5 is not completely characterized, current data are consistent with the hypothesis that these molecules contribute to *in vivo* infection by macrophage-tropic primary HIV-1 variants. The tissue distribution of CCR5 has been reported to be restricted to KG-1A promyeloblastic cells (Samson et al., 1996), but more recent data suggest that it is expressed in both CD4-positive and CD8-positive human PBMC as well as in cells of the myeloid lineage (C.G., unpublished observations and Raport et al., 1996). The latter distribution is consistent with that expected based upon the known host cell range of primary HIV-1 isolates. The expression of CCR3 appears to be more restricted, with high levels of expression in eosinophils and little expression in peripheral blood T lymphocytes (Daugherty et al., 1996; Kitaura et al., 1996, Ponath 1996b). The latter observation suggests that CCR3 could not be the sole factor facilitating the infection of primary HIV-1 isolates, all of which replicate in PBMC. While the involvement of CCR5 is likely to be relevant to a greater variety of HIV-1 target cells, CCR3 may play an important role in a limited number of cell types. eosinophils, which express high levels of CCR3 (Daugherty et al., 1996; Kitaura et al., 1996; Ponath et al., 1996b), also express CD4 and have been reported to be infectible by HIV-1 (Freedman et al., 1991; Weller et

al., 1995). In one of these studies (Freedman et al., 1991), two primary HIV-1 isolates but not a laboratory-adapted virus were able to replicate on bone marrow-derived eosinophil cultures. It is not known if the ability of monocytes to respond to high concentrations of eotaxin (Ponath et al., 1996a) indicates a low level of expression of CCR3 on these cells, or the presence of another low affinity receptor. MCP-3, one of the CCR3 ligands, is an important chemotactic factor for dendritic cells (Sozzani et al., 1995), which have been suggested to play an important role in HIV-1 transmission across mucosal barriers (Spira et al., 1996). The expression of CCR3 on these and other potential HIV-1 target cells merits further investigation. The expression of CCR3 significantly enhanced infection by a smaller subset of primary HIV-1 than did CCR5 expression. Although infection mediated by several of the primary HIV-1 envelope glycoproteins was not detectably affected by CCR3 expression, significant CCR3 effects were observed for the YU2 and ADA envelope glycoproteins. This result suggests that heterogeneity in chemokine receptor utilization may occur even among macrophage-tropic primary HIV-1 isolates. It is perhaps relevant that, while all primary HIV-1 isolates are more resistant to antibody neutralization than are laboratory-adapted viruses (Montefiori et al., 1991; Bou-Habib et al., 1991; Burton et al., 1994; Mascola et al., 1994; Moore et al., 1995; Sullivan et al., 1995; Karlsson et al., 1996), infection by the ADA and YU2 viruses is actually enhanced by neutralizing antibodies (Sullivan et al., 1995). It is unknown whether antibody-mediated enhancement is related to utilization of CCR3, but the magnitude of both antibody and CCR3 enhancement was greatest on viruses containing the YU2 envelope glycoproteins. These

observations raise the possibility that a subset of primary HIV-1 exhibits previously unsuspected properties allowing continued replication in particular cell types in the presence of neutralizing antibodies. The YU2 sequences were
5 directly cloned into phage vectors from the central nervous system of an infected patient, thus avoiding even minimal passage on PBMC (Li et al., 1991). Isolation of HIV-1 on peripheral blood T lymphocytes, which do not express CCR3, in the absence of neutralizing antibodies may remove
10 selection pressure for viruses that can utilize these molecules to enhance infection. Establishment of different *in vitro* culture systems may allow the identification of additional HIV-1 isolates that can efficiently utilize CCR3. The contribution of CCR3 to primary HIV-1 infection of
15 different target cells *in vivo* and the relationship between CCR3 use and resistance to neutralizing antibodies will be evaluated in future studies.

The involvement of receptors for the β chemokines in HIV-1 infection explains the sensitivity of macrophage-
20 tropic primary HIV-1 isolates, but not laboratory-adapted isolates, to inhibition by RANTES, MIP-1 α AND MIP-1 β (Cocchi et al., 1995). Both CCR3 and CCR5 have been shown to be responsive to RANTES (Daugherty et al., 1996; Samson et al., 1996; Ponath et al., 1996b). The increased HIV-1 inhibitory
25 activity of RANTES compared with MIP-1 α and MIP-1 β suggests that CCR5 may not be solely responsible for mediating this inhibition, since CCR5 has been reported to exhibit greater sensitivity to MIP-1 α than to RANTES (Samson et al., 1996). The involvement of another chemokine receptor, such as CCR3,
30 which is responsive to RANTES but not to MIP-1 α or MIP-1 β , in the HIV-1 inhibitory effect could explain the data. Our

data on eotaxin inhibition of CCR3-mediated HIV-1 infection suggest that suppression of virus infection may be a general consequence of ligand binding to chemokine receptors that are specifically used by particular HIV-1 strains.

- 5 Additional work will be required to understand if the inhibition of HIV-1 infection by the β chemokines involves competitive or non-competitive inhibition of binding of the HIV-1 envelope glycoproteins, receptor down-modulation triggered by ligand binding, or indirect receptor-mediated
10 signaling events.

- The ability of CCR3 and CCR5 to enhance both syncytium formation and the early phase of HIV-1 infection suggests that these molecules facilitate virus binding to the target cell and/or membrane fusion. The structure of the gp120 V3
15 loop, previously shown to specify target cell-dependent membrane fusion efficiency (Cheng-Mayer et al., 1990; O'Brien et al., 1990; Hwang et al., Westervelt et al., Ivanoff et al., 1991; Westervelt et al., 1992; Bergeron et al., 1992; Chesebro et al., 1992), determined the ability of
20 the viral envelope glycoproteins to utilize CCR3 and CCR5 as accessory factors for entry. The simplest model for post-CD4 binding events in HIV-1 entry would involve a direct interaction between the viral envelope glycoproteins and the chemokine receptors. The variability of gp120 tropism
25 determinants, in particular the V3 loop, among HIV-1 strains contrasts with the minimal polymorphism observed in particular chemokine receptors. Our data indicate that infection by geographically and phylogenetically diverse HIV-1 isolates can be facilitated by the same CCR5 molecule.
30 If direct envelope glycoprotein-chemokine receptor interaction occurs, it may involve conserved structures on the gp120 variable loops not apparent from inspection of

primary amino acid sequences. This situation may be analogous to the binding of apparently diverse chemokines by the same chemokine receptor. Alternatively, conserved gp120 or gp41 structures influenced indirectly by variable loop configurations may directly interact with the chemokine receptors. While CCR3 and CCR5 are closely related among the chemokine receptors (Daugherty et al., 1996; Ponath et al., 1996b; Raport et al., 1996; Samson et al., 1996), the relationship of either of these molecules to CCR1, which did not affect HIV-1 infection in our hands, is even greater. Again, simple inspection of primary sequences does not reveal determinants unique to CCR3 and CCR5 that might be targets for HIV-1 interaction. An alternative model is that the chemokine receptors affect the target membrane and/or CD4 in ways conducive to entry by viruses with particular envelope glycoprotein configurations, without directly contacting viral components. It is also possible that G protein-mediated signaling plays a role in HIV-1 infection. Additional studies should distinguish among these possibilities.

The involvement of G protein-coupled receptors in two other instances of infection with pathogens has been reported. The Duffy antigen receptor, which binds both α and β chemokines, facilitates invasion by the malarial parasite, *Plasmodium vivax* (Horuk et al., 1993; Chaudhuri et al., 1993). Similarly, the progression from colonization to infection with *Streptococcus pneumonia* is facilitated by expression of the platelet-activating factor receptor (Cundel et al., 1995).

The β chemokine receptors identified here may represent important host components that specify susceptibility to HIV-1 infection or, in already infected individuals,

determine viral burden and rate of disease progression. Endogenous levels of RANTES, MIP-1 α and MIP-1 β expression in CD4-positive lymphocytes were higher in some individuals that remained uninfected despite multiple sexual exposures to HIV-1 infected partners (Paxton et al., 1996). If direct interaction between viral components and β chemokine receptors occur, inappropriate signaling events may be initiated that contribute to pathogenesis. A better understanding of the interaction of HIV-1, β chemokines and their receptors may clarify the contribution of these elements to virus transmission and pathogenic outcome, and may suggest approaches for intervention.

TABLE LEGENDS

Table 1. HeLa target cells expressing the molecules shown were infected with recombinant HIV-1 viruses containing the envelope glycoproteins listed. In some of the experiments, the transfected HeLa target cells were treated with sodium butyrate prior to infection. CAT activity (percentage conversion of chloramphenicol to acetylated forms per unit of lysate) was determined. the values reported represent the mean value from duplicate experiments; standard deviation was less than 25% of the mean values. ND = not determined. The surface expression of the CCR2, CCR3, IL8RA, IL8RB and PAF-Rf proteins was documented by FACS using specific monoclonal antibodies (data not shown). The surface expression of the CCR1F, CCR3F and CCR5F proteins was directly compared by using a monoclonal antibody reactive with the epitope tag (FLAG tag) on the amino terminus of each of these molecules. The mean fluorescein intensities observed were: Background: 9.9; CCR1F: 233.8; CCR3F: 12.6; and CCR5F: 19.3. Background

values were obtained by using only the secondary antibody (FITC-conjugated anti-mouse IgG) in the FACS analysis.

Table 2. HeLa cells expressing CD4 and chemokine receptors were incubated with recombinant viruses containing the designated envelope glycoproteins, and CAT activity measured. The ADA and YU2 envelope glycoproteins were derived from macrophage-tropic primary HIV-1 viruses from North America (clade B). The Br20-4, Br25-9, Rw20-5, Th966 and Tn243 envelope glycoproteins were derived from macrophage-tropic primary HIV-1 viruses. The phylogenetic classification and geographic origin of these viruses are as follows: Br20-4 (clade B, Brazil), Br25-9 (clade C, Brazil), Rw20-5 (clade A, Rwanda), Th966 (clade E, Thailand) and TN243 (clade E, Thailand) (Gao et al., 1996; Karlsson et al., 1996). The HXBc2 envelope glycoproteins were derived from a highly laboratory-adapted clade B HIV-1 isolate. The A-MuLV envelope glycoproteins were derived from the amphotropic murine leukemia virus (Landau et al., 1991). The values reported represent mean CAT activity per unit of cell lysate, as described in the Table 1 legend.

Table 3. HeLa-CD4 cells expressing chemokine receptors were incubated with recombinant viruses containing wild-type of chimeric envelope glycoproteins, and CAT activity measured. The HXBc2 (ADA-V3) and HXBc2 (YU2-V3) envelope glycoproteins are identical to the HXBc2 envelope glycoprotein except for a substitution of the ADA or YU2 V3 loop in the gp120 glycoprotein (Westervelt et al., 1992; Carillo et al., 1993). The HXBc2 (YU2-V1/V2) chimeric envelope glycoprotein contains a substitution of the V1/V2 loops from the YU2 virus into the HXBc2 gp120 glycoprotein. ND = not determined.

Table 1

| HIV-1 Envelope Glycoproteins | | | | | |
|-------------------------------------|------|------|------|--------|--------|
| Molecules Expressed in Target Cells | None | ADA | YU2 | Br20-4 | HXBc-2 |
| CD4 (+CD2 control) | 0.29 | 1.5 | 1.1 | 0.79 | 53.5 |
| CD4+CCR1 | ND | 1.3 | 1.1 | 0.79 | ND |
| CD4 +CCR1F | 0.25 | 2.0 | 2.0 | 1.1 | 51.9 |
| CD4 + CCR1F (sodium butyrate) | ND | ND | 2.0 | 1.1 | 51.9 |
| CD4 + CCR2 | 0.30 | 2.1 | 1.7 | 0.85 | 54.2 |
| CD4 + CCR3 | 0.25 | 14.2 | 35.0 | 1.2 | 53.1 |
| CCR3 | ND | 1.5 | 0.61 | 1.2 | ND |
| CD4 + CCR3F | 0.20 | 13.7 | 17.8 | 1.6 | 54.1 |
| CD4 + CCR3F (sodium butyrate) | ND | ND | 32.7 | ND | ND |
| CD4 + CCR5 | 0.17 | 52.4 | 49.0 | 25.3 | 53.6 |
| CCR5 | ND | 1.3 | 0.71 | 1.3 | ND |

Table 1 Continued

| | | | | | |
|-------------------------------|------|------|------|------|------|
| CD4 + CCR5F | 0.20 | 61.9 | 51.0 | 39.8 | 53.4 |
| CD4 + CCR5F (sodium butyrate) | ND | ND | 81.9 | ND | ND |
| CD4 + IL8RA | 0.28 | 1.5 | 0.84 | 0.64 | 57.0 |
| CD4 + IL8RB | 0.41 | 1.9 | 1.3 | 0.64 | 55.1 |
| CD4 + HUSMTSR | 0.19 | 1.1 | 0.68 | 0.45 | 53.0 |
| CD4 + Duffy | 0.08 | 0.41 | 0.33 | 0.22 | 53.4 |
| CD4 + PAF - Rf | ND | 0.92 | 0.37 | 0.79 | ND |
| CD4 + FMLP - Rf | ND | 2.0 | 1.0 | | ND |
| CD4 + C5a | ND | 0.66 | 0.73 | 0.45 | ND |

Table 2

| Molecules Expressed In Target Cells | Envelope Glycoproteins | | | | | | | | | |
|--|------------------------|-------|-------|--------|--------|--------|-------|-------|-------|--------|
| | None | ADA | YU2 | BR20-4 | Br25-9 | Rw20-5 | Th966 | TN243 | HXBc2 | A-MuLV |
| CD4 (+CD2 control) | 0.58 | 4.8 | 5.3 | 3.0 | 2.3 | 3.1 | 1.6 | 1.5 | 82.1 | 1742 |
| CD4 +CCR1F | 0.33 | 5.7 | 5.0 | 3.6 | 3.5 | 8.4 | 1.4 | 2.5 | 131.7 | 1489 |
| CD4 - CCR3 | 0.35 | 45.9 | 70.5 | 3.0 | 5.0 | 5.4 | 1.3 | 1.5 | 111.3 | 1521 |
| CD4 + CCR5 | 0.36 | 102.3 | 103.9 | 49.8 | 11.6 | 70.4 | 16.7 | 16.6 | 104.9 | 812 |

TABLE 3

| Molecules Expressed in HeLa-CD4 Target Cells | Envelope Glycoprotein | | | | | |
|---|-----------------------|------|-------|-------------------|-------------------|----------------------|
| | ADA | YU2 | HXBc2 | HXBc2 (ADA-V3) | HXBc2 (YU2-V3) | HXBc2 (YU2-V1/V2) |
| CD2 | 1.4 | 0.88 | 546 | 1.3 | 0.87 | 914 |
| CCR3 | 19.0 | 73.4 | 542 | 40.8 | 5.9 | 1016 |
| CCR5 | ND | ND | 543 | 37.6 | 40.9 | 417 |

To study expression of CCR5, CXCR4 and CCR3 in the brain, we performed RT-PCR analysis of primary human brain cultures using oligonucleotide primer pairs specific for
5 each chemokine receptor.

METHODS

Primary Brain Cultures

Primary human brain cultures were prepared from 13 to
10 18 weeks' gestation fetal abortuses, plated in 24-well plates (250,000 cells per well), and maintained in DMEM containing 10% calf serum for 10 to 21 days prior to infection or detection of chemokine receptor expression as described (Shi, B., et al., 1996). Tissue was procured in
15 accordance with institutional regulations. These cultures contain a mixture of astrocytes (70-90%), neurons (10-30%), microglial cells (1-5%), and fibroblast (1-5%) (Shi, B., et al., 1996).

Production of HIV-1 Viruses. Recombinant GFP or luciferase
20 reporter viruses were generated by cotransfection of COS-7 or 293 cells with 20 µg of pNL4-3env GFP or pNL4-3envLUC and 4 µg of pSVIIIenv plasmids encoding different HIV-1 Envs or pSVMLVenv using the calcium phosphate method (He, J., et al., 1995). The pNL4-3env GFP plasmid, which encodes full-
25 length NL4-3 HIV-1 proviral DNA with a frameshift in env and expresses GFP in place of nef, was constructed by replacing the alkaline phosphatase (AP) gene in pHIV-AP (He, J., et al., 1995) with the GFP gene using NotI and XhoI restriction sites introduced into pEGFP-1 (Clontech) by PCR
30 amplification. pNL4-3env LUC, which encodes full-length env-defective NL4-3 HIV-1 proviral DNA and expresses the luciferase enzyme, was similarly constructed by replacement of the AP gene in pHIV-AP with the luciferase gene from

64

pGEM-luc (Promega). The pSVIIIenv plasmids, which express Env proteins from different strains of HIV-1, and the pSVMLV-env plasmid, which expresses the amphotropic murine leukemia virus envelope glycoproteins have been described (Choe, H., et al., 1996). Supernatants containing virus were collected 48 h after transfection, quantitated by RT assay (Shi, B., et al., 1996), and stored at -80° C. A similar method was used to produce HIV-1 CAT reporter viruses pseudotyped with different HIV-1 Envs (Choe, H., et al., 1996).

HIV-1 Entry and Chemokine Inhibition Assays

Primary brain cultures were infected by incubation with recombinant virus (5,000 RT units) pseudotyped with the different Envs in 1 ml of medium. After 16 h of incubation at 37° C, the medium was removed and the cultures were washed three times prior to addition of fresh medium. After an additional 72 h at 37° C, the cells were fixed in 4% paraformaldehyde in PBS for visualization of GFP and immunofluorescence staining or lysed for determination of luciferase activity using commercially available reagents (Promega) after normalization for the same protein concentration. For chemokine or antibody inhibition experiments, cultures were preincubated for 60 min at 37° C in 0.5 ml medium with chemokine (500 ng/ml, except for SDF-1, which was used at 2.5 µg/ml) or antibody (20 µg/ml) prior to infection. Subsequently, infections were performed by addition of recombinant virus in an equal volume of medium without additional chemokine or antibody for 16 h at 37° C. The cells were then washed and fresh medium without chemokine or antibody was added. The cells were cultured for an additional 72 h at 37° C, and then processed as

65

described above. Results were expressed as the luciferase activity (cpm) following subtraction of the mean background levels obtained with no Env. For antibody inhibition experiments, Cf2Th canine thymocytes were transfected with plasmids expressing CD4 and either CCR3, CCR5, or CXCR4 as described (Choe, H., et al., 1996). The transfected cells were incubated either in the absence or presence of the 7B11 antibody (3 µg/ml) for 1 h at 37° C. Subsequently, the cells were infected by HIV-1 CAT reporter viruses pseudotyped with an HIV-1 Env (YU2 Env for the CCR3 and CCR5 transfectants, HXB2 Env for the CXCR4 transfectants) and CAT activity was measured in the transfected cells 60 h after infection (Choe, H., et al., 1996).

15 Immunofluorescence Staining

Immunofluorescence staining of fixed cultures with the indicated primary antibodies followed by FITC- or rhodamine-conjugated secondary antibodies (Sigma) was performed as described (Shi, B., et al., 1996). The dilutions for the primary antibodies were: mouse anti-CD68 monoclonal (EBM11) (Dako), 1:10; rabbit anti-GFAP (sigma), 1:100; mouse anti-CCR3 monoclonal (7B11) (Heath, H., et al., In Press), 1:50. Labeling with RCA-1 conjugated to rhodamine (10 µg/ml) (Vector Laboratories) was performed for 1 h at room temperature. For staining of primary brain cultures, the anti-CCR3 monoclonal antibody was detected by incubation with biotinylated horse anti-mouse IgG (5µg/ml) for 30 min followed by avidin-FITC (20µg/ml) for 15 min (Vector Laboratories).

30

Reverse Transcription-polymerase Chain Reaction (RT-PCR)

Total RNA was isolated (Oncor) and 0.5 µg was used for

66

cDNA synthesis using Superscript II RNase H-reverse transcriptase and random hexamer primers (Gibco-BRL). One tenth of this reaction was used as a template for PCR amplification with AmpliTaq DNA polymerase (Perkin-Elmer)

5 (CXCR4 primers (SEQ ID NO:6), 5'-GACCGCTACCTGGCCATT-3; and (SEQ ID NO:7) 5'-GTTGTAGGGCAGCCAGCA-3'; CCR5 primers, (SEQ ID NO:8) 5'-AATCTTCTTCATCATCCTCC-3' and (SEQ ID NO:9) 5'-TCTCTGTCACCTGCATAGC-3'; CCR3 primers, (SEQ ID NO:10) 5'-TCCTTCTCTCTTCCTATCAATC-3' and (SEQ ID NO:11)

10 5'-GGCAATTTTCTGCATCTG-3') for 30 cycles at 94° C for 1 min, 50° C (CXCR4) or 55° C (CCR5 and CCR3) for 1 min, and 72° C for 1 min. CCR5, CXCR4, and CCR3 transcripts were detected in primary brain cultures (Fig. 6A). The identity of these transcripts was confirmed by DNA sequencing of the PCR

15 products (data not shown). CCR3 transcripts were relatively abundant. Based on this finding, we examined whether CCR3 is expressed in microglia by double immunofluorescence staining with an anti-CCR3 monoclonal antibody (Heath, H., et al.) and the microglial cell marker *Ricinus communis* agglutinin I

20 (RCA-1). CCR3 was expressed in >95% of microglia in primary brain cultures and was not detected in other brain cell types (Fig 6B). CCR3 expression in microglia was also detected in autopsy brain tissue from two normal adults and two patients with Alzheimer's disease (Fig. 6C) and data not

25 shown. Similar experiments using an anti-CCR5 monoclonal antibody showed that microglia also express CCR5 (data not shown). The microglia in these specimens did not stain with monoclonal antibodies directed against galactosyl ceramide or glial fibrillary acidic protein (data not shown).

30 We then examined the ability of HIV-1 Env proteins with different chemokine receptor specificity to mediate virus entry into primary human brain cultures containing microglia and astrocytes. We used ADA (Westervelt, P., et al., 1991),

67

YU2 (Li, Y., et al., 1991), and Br20-4 (Choe, H., et al., 1996) as M-tropic Envs, and HXB2 as a T-tropic Env. We also tested the dual-tropic 89.6 Env, which supports broader HIV-1 tropism (Collman, R., et al., 1992). The chemokine

5 receptor utilization and biological properties of these HIV-1 Envs are summarized in Table 4. An env-defective HIV-1 reporter virus that expresses the green fluorescent protein (GFP) was constructed. Complementation of this virus with HIV-1 Env allows a single round of infection to occur, and

10 infected cells can be detected by expression of GFP. Recombinant HIV-1 GFP reporter viruses were used to infect primary human fetal brain cultures. To identify HIV-1 infected cells *in situ* GFP fluorescence was visualized in combination with cell-specific markers for microglia and

15 astrocytes (Fig. 7). The results are summarized in Table 4. The most efficient infection of microglia was mediated by the YU2, ADA and 89.6 Envs, followed by the Br20-4 Env (Table A1). Microglial infection mediated by the HXB2 Env was relatively inefficient. A minor fraction of astrocytes

20 (2-4%) was infected by viruses with YU2, ADA, 89.6, Br20-4, or HXB2 Envs, indicating that a low efficiency of HIV-1 entry into astrocytes can be mediated by either M-tropic or T-tropic Envs. The level of GFP expression in astrocytes was generally lower than that seen in microglia, consistent

25 with previous studies demonstrating that HIV-1 gene expression in astrocytes is restricted (Takahashi, K., et al., 1996). These results demonstrate that M-tropic HIV-1 viruses that use CCR5 and CCR3 as co-receptors infect microglia efficiently, whereas a T-tropic virus that uses

30 CXCR4 infects these cells at relatively low efficiency.

The natural ligands for the chemokine receptors have been shown to inhibit the entry of particular HIV-1 isolates that use these receptors (Feng, Y., et al., 1996; Deng,

H.K., et al., 1996; Dragic, T., et al., 1996; Alkhatib, G., et al., 1996; Choe, H., et al., 1996; Cocchi, F., et al., 1995; Bleul, C.C., et al., 1996; Oberlin, E., et al., 1996), MIP-1 α , MIP-1 β , and RANTES, chemokines (Harouse, J.M., et al., 1989; Tornatore C., et al., 1991) that bind CCR5, inhibit infection by M-tropic but not T-tropic HIV-1 isolates (Deng, H.K., et al., 1996; Dragic, T., et al., 1996; Alkhatib, G., et al., 1996; Cocchi, F., et al., 1995). Similarly, stromal cell-derived factor-1 (SDF-1) inhibits entry by T-tropic or dual-tropic HIV-1 isolates that use CXCR4 (Bleul, C.C., et al., 1996; Oberlin, E., et al., 1996). Infection by the subset of M-tropic isolates that utilize CCR3 as a co-receptor is inhibited by eotaxin (Choe, H., et al., 1996), the major CCR3 ligand (Ponath, P., et al., 1996; Daugherty, B.L., et al., 1996; Heath, H., et al., in press). We tested the ability of chemokines to inhibit HIV-1 infection of primary brain cultures. Chemokine blocking experiments were performed using env-defective HIV-1 luciferase reporter viruses pseudotyped with different HIV-1 Envs. The amphotropic murine leukemia virus (MLV) Env was used to control for possible nonspecific inhibitory effects. The efficiency of the early phase of virus replication during a single-cycle infection was determined by measuring luciferase activity in the primary brain cultures at 72 h after infection (Fig. 8). The relative efficiency of virus entry mediated by the different HIV-1 Envs was similar to that observed using the HIV-1 GFP reporter viruses. We initially tested MIP-1 β , eotaxin, and SDF-1 since these chemokines show selective binding to either CCR5, CCR3, or CXCR4, respectively. MIP-1 β and eotaxin inhibited infection with HIV-1 luciferase reporter viruses containing the YU2 or ADA Envs by 70-80% (Fig. 8A).

In contrast, infection with viruses containing the Br20-4 or 89.6 Env was inhibited by MIP-1 β , but was not significantly inhibited by eotaxin. MIP-1 β and eotaxin had no inhibitory effect on the virus with the HXB2 Env. SDF-1 inhibited infection by viruses with the 89.6 or HXB2 Env, but not the YU2, ADA, or Br20-4 Env. MCP-1 which does not bind CCR5, CC3, or CXCR4, had no inhibitory effect on any of the viruses tested. None of the chemokines tested inhibited infection by virus with the MLV Env (Fig. 8B). These results are consistent with the known chemokine receptor utilization of the different HIV-1 Envs (Table 4) and suggest that chemokines that bind either CCR5, CCR3, or CXCR4 can inhibit infection of CNS target cells by HIV-1 isolates with the same chemokine receptor selectivity.

Our finding that eotaxin showed potent blocking activity for viruses bearing the YU2 or ADA Envs led us to examine further the possibility that CCR3 is a co-receptor for HIV-1 infection of microglia. To address this question, we tested the blocking activity of the 7B11 monoclonal antibody, which specifically recognizes CCR3 and completely blocks the binding and signaling of the known CCR3 ligands (Heath, H., et al., In Press). To test whether the 7B11 antibody inhibits HIV-1 entry into CCR3-expressing cells and to confirm its specificity, Cf2Th canine thymocytes transfected with plasmids expressing CD4 and either CCR3 or CCR5 (Choe, H., et al.) were infected with recombinant HIV-1 CAT reporter viruses containing the YU2 Env in the absence or presence of the antibody. Cf2Th cells transfected with plasmids expressing CD4 and CXCR4 were infected with the HIV-1 CAT reporter virus containing the HXB2 Env in parallel experiments. The 7B11 monoclonal antibody blocked infection of CCR3-expressing cells, but not CCR5- or CXCR4-expressing cells, as determined by inhibition of CAT activity in the

70

target cells 60 h after infection (Fig. 8D). These findings indicate that the anti-HIV-1 effect of the 7B11 antibody is specific for infections in which CCR3 is used as a co-receptor.

5 We then examined the blocking activity of the anti-CCR3
monoclonal antibody in primary brain cultures. The anti-
CCR3 antibody inhibited infection by HIV-1 luciferase
reporter viruses with the YU2 or ADA Env with an efficiency
comparable to that of eotaxin (Fig. 8C). To test whether
10 ligands that bind to both CCR3 and CCR5 show greater
blocking activity than ligands selective for either CCR3 or
CCR5, we also tested the blocking activity of RANTES, a
ligand for both receptors, and the combination of eotaxin
and MIP-1 β was not significantly greater than that of
15 eotaxin alone (Fig. 8C). The chemokines and the 7B11
antibody had no inhibitory effect on viruses with the MLV
Env (Fig 8B). We also tested the inhibitory effect of the
anti-CD4 monoclonal antibody OKT4A, which blocks gp120-CD4
binding. The OKT4A antibody inhibited infection by HIV-1
20 luciferase viruses containing the YU2, ADA, Br20-4, or 89.6
Envs by 70-80%, while infection by virus with the HXB2 Env
was inhibited by 50% (data not shown). In contrast, the
infection of the CD4+ Jurkat T cell line was inhibited by
>95% using the same assay conditions.

25 The preceding experiments demonstrate that CCR3 and CCR5 are used for HIV-1 infection of primary brain cultures. To determine whether CCR3 and CCR5 are used for HIV-1 infection of microglia, the inhibitory effects of eotaxin, MIP-1 β , and the 7B11 anti-CCR3 antibody were examined by
30 direct visualization of infected target cells using HIV-1-GFP reporter viruses. Double labeling with cell-specific markers showed that eotaxin, MIP-1 β , and anti-CCR3 inhibited

71

70-80% of microglial infection by HIV-1 GFP reporter viruses with the YU2 Env, as determined by counting the percentage of GFP-positive, CD68 positive cells. These results support a necessary role of CCR3 and CCR5 in HIV-1 infection of
5 microglia.

The studies reported herein suggest that CCR3 and CCR5 both serve as major co-receptors with CD4 for HIV-1 infection of brain microglia. The M-tropic primary HIV-1 isolates infect peripheral blood monocyte/macrophages and
10 brain-derived microglia more efficiently than T-tropic isolates. The use of both CCR3 and CCR5 for microglial entry differs from infection of blood-derived monocyte/macrophages, which express CCR5 [Deng, H.K., et al., *Nature* 381:667-673 (1996); Alkhatib, G., et al.,
15 *Science* 262:1955-1958 (1996)] but do not express CCR3. Our results provide an explanation for the observation that subsets of M-tropic primary HIV-1 isolates use CCR3 as well as CCR5 as a second receptor (Choe, H., et al., 1996; Doranz, B.J., et al., 1996). Our study predicts that such
20 viruses reside in the CNS and that the unique pattern of chemokine receptor expression in microglia selects for particular features of the viral envelope glycoproteins. The finding that the YU2 virus, which was cloned directly from brain, (Li, Y., et al., 1992) shows more efficient CCR3
25 usage than M-tropic or dual-tropic isolates derived from the blood (i.e. ADA, Br20-4, 89.6 and ELI) and the observation that some primary isolates show preferential replication in microglia compared to blood-derived monocyte/macrophages (Strizki, J.M., et al.) are consistent with this prediction.

30 The finding that MIP-1 α and MIP-1 β are induced in the brain of AIDS patients raises the additional possibility that viruses continue to replicate in the CNS in the

- presence of these CCR5 ligands by using CCR3 for virus entry.

5 Our data indicate that the CCR3 and CCR5 ligands interfere with HIV-1 entry into microglia more than might be expected from inhibition of independently functioning co-receptors. Cooperatively between CCR3 and CCR5 in HIV-1 entry or between ligand-mediated mechanisms of HIV-1 inhibition is implied by these results. The identification of CCR3 as a co-receptor contributing to efficient HIV-1
10 infection of microglia confirms the new therapeutic strategies to inhibit HIV-1 replication in the CNS as discussed herein.

Table 4.

HIV-1 infection of microglia and astrocytes in primary brain cultures mediated by Env proteins with different chemokine receptor utilization

| HIV-1 ENVELOPE | CLASSIFICATION | CHEMOKINE RECEPTOR UTILIZATION | Microglia | Astrocytes |
|-------------------|---------------------------------|--------------------------------|-----------|------------|
| YU2 | M-tropic primary, NSI | CCR5, CCR3 | 44 ± 4 | 3.8 ± 0.8 |
| ADA | M-tropic primary, NSI | CCR5, CCR3 | 42 ± 6 | 3.3 ± 0.2 |
| Br20-4 | M-tropic primary, NSI | CCR5 | 36 ± 1 | 3.2 ± 0.8 |
| 89.6 | Dual-tropic primary SI | CXCR4, CCR5, (low CCR3) | 48 ± 2 | 2.4 ± 0.9 |
| HXB2 | T-tropic laboratory-adapted, SI | CXCR4 | 10 ± 0 | 3.0 ± 0.5 |

73

The efficiency of HIV-1 entry was determined by single-cycle infections using HIV-1-GFP reporter viruses pseudotyped with different HIV-1 Envs. The chemokine receptor utilization is derived from the method of Choe, et al. The efficiency of HIV-1 entry for each Env is expressed as the percentage of CD-68-positive (microglia) or GFAP-positive (astrocytes) cells labeled with GFP, as determined by counting ten random fields (magnification: 200X). Data shown are the mean ± s.d. of duplicates from a representative experiment. Results were comparable in four independent experiments, although the maximum HIV-1 entry ranged from 30-45% for microglia and from 2-5% for astrocytes between different donors.

Abbreviations: M-tropic, macrophage-tropic; T-tropic, T-cell line tropic; NSI, non-syncytium-inducing; SI, syncytium inducing.

Primary macrophage-tropic and laboratory-adapted human immunodeficiency viruses type 1 (HIV-1) require particular chemokine receptors, CCR5 and CXCR4, respectively, in addition to the primary receptor, CD4, for efficient entry into target cells [Feng, Y., et al., *Science* 272:872-877 (1996); Choe, H., et al., *Cell* 85:1135-1148 (1996); Doranze, B.J., et al., *Cell* 85:1149-1158 (1996); Dragic, T., et al., *Nature* 381:661-666 (1996); Deng, H., et al., *Nature* 381:661-666 (1996)]. The following data demonstrates that a complex of the exterior envelope glycoprotein, gp120, of macrophage-tropic primary HIV-1 and soluble CD4 interacts specifically with CCR5 and inhibits the binding of the natural CCR5 ligands, MIP-1 α and MIP-1 β [Samson, M., et al., *Biochemistry* 271:3362-3367 (1996); Raport, C., et al., *J Biol Chem* 271:17161-17166 (1996)]. The apparent affinity of the gp120-CCR5 interaction was dramatically lower in the absence of soluble CD4. Additionally, in the absence of gp120, an interaction between a two-domain CD4 fragment and CCR5 was observed. A gp120 fragment retaining the CD4 binding site and overlapping epitopes was able to interact with CCR5 only if the V3 loop, which can specify HIV-1 tropism and chemokine receptor choice [Choe, H., et al., *Cell* 85:1135-1148 (1996); Cheng-Mayer, C., et al., *J Virol* 64:4390-4398 (1990); Chesebro, B., et al., *J Virol* 65:5782-5789 (1991); Hwang, S., et al., *Science* 253:71-74 (1991); Westervelt, P., et al., *J Virol* 66:2577-2582 (1992)], was also present on the molecule. Neutralizing antibodies directed against either CD4-induced or V3 epitopes on gp120 blocked the interaction of gp120 CD4 complexes with CCR5. These results indicate that HIV-1 attachment to CD4 creates a high-affinity binding site for a chemokine receptor such as CCR5, leading to membrane fusion and virus entry.

METHODS

Cells

The murine pre-B lymphoma line, L1.2, was stably
5 transfected with CCR5 cDNA, tagged at the N-terminus with a
FLAG epitope (Kodak), in the pMRB101 expression vector, as
described [Ponath, P., et al., *J Exp Med* 183:2437-2448
(1996)]. The pMRB101 plasmid is a derivative of
Ee6hcmvbglii that contains the E. coli gpt gene and was
10 kindly provided by Martin Robinson (CellTech). The cell
surface expression of CCR5 was monitored by staining with an
anti-FLAG antibody, and cells with a high level of CCR5
expression were selected by several rounds of limiting
dilution and rescreening. L1.2 cells stably expressing CCR1
15 were kindly provided by James Campbell and Eugene Butcher
(Stanford University). Scatchard analysis of MIP-1 α
binding to CCR1-L1.2 cells revealed a dissociation constant
of 8 nM and 2×10^4 binding sites per cell (S. Qin,
unpublished results).

20

Chemokine Binding and Competition Assays

¹²⁵I-labeled human MIP-1 α and MIP-1 β and unlabeled
chemokine were purchased from DuPont NEN (Boston, MA) and
Peprotech (Rocky Hill, NJ), respectively. CCR5F-L1.2 cells
25 were washed and resuspended in binding buffer (50 mM HEPES,
pH7.5, 1 mM CaCl₂, 5mM MgCl₂, and 0.5% BSA) at a
concentration of 5×10^8 cells/ml. For binding and
competition studies, which were conducted in a final volume
of 100 μ l, gp120 glycoproteins were mixed with soluble CD4
30 on ice for 5-10 minutes, after which monoclonal antibodies
were added if appropriate. After another 5-10 minutes, 25
 μ l of cell suspension (1.25×10^5 cells) was added, followed

76

by radiolabeled chemokine (final concentration 0.1 nM). The reactions were then incubated at 37° C for 30-45 minutes and stopped by transferring the mixture to GFB filter plates, which were then washed twice with binding buffer containing 0.5 M NaCl. The plates were dried, immersed in MicroScint scintillation fluid, and counted. The total binding was determined by including only radiolabeled chemokine and cells in the reaction. Non-specific (background) binding was determined in the presence of 100 nM unlabeled chemokine. The percentage of inhibition was calculated using the following formula:

$$\% \text{ Inhibition Ligand Binding} = 100 - 100 \times \frac{(S-B)}{(T-B)},$$

where S is the test sample, B is the background, and T is the total binding. Each experiment was performed twice with duplicates.

20 Recombinant Glycoproteins

All of the gp120 glycoproteins were produced from stably transfected *Drosophila* Schneider 2 cells, using the pMT vector and selectable marker, pc hygro [Culp, J.S., et al., *Biotechnology* 9:173-177 (1991)]. The JR-FL and BAL gp120 proteins were previously described [Ivey-Hoyle, M., *Proc Natl Acad Sci USA* 88:512-516 (1991)] and were generously provided by Dr. Raymond Sweet (SmithKline Beecham). The BAL gp120 derivative contains an amino terminal deletion of 32 residues compared with the wild-type gp120 glycoprotein. The YU2 glycoproteins were produced from a chimeric env gene, containing YU2 sequences from Bgl II (nucleotide 6620) to BG1 II (nucleotide 7200) in an HXBc2 background. The ΔC1 proteins contain deletions up to and including residue 82. The ΔV1/2 and ΔV3 proteins contain deletions

equivalent to the Δ 128-194 and Δ 298-329 deletions, respectively, previously described for the HXBc2 glycoprotein [Wyatt, R., et al., *J Virol* 69:5723-5733 (1995)]. The Δ C5 proteins contain a deletion of the

5 carboxy-terminal 19 residues of the mature gp120 glycoprotein. All gp120 proteins utilize the tissue plasminogen activator signal sequence for translocation into the endoplasmic reticulum. Protein expression of recombinant YU2 and HXBc2 derivatives was induced by

10 transfer of *Drosophila* lines into serum-free medium containing 750 mM CuSO_4 for seven days at 25° C. Recombinant proteins were purified by passage of cell supernatants over an F105 monoclonal antibody column, which was extensively washed with PBS containing 500 mM NaCl and

15 then reequilibrated in PBS containing 150 mM NaCl. The gp120 glycoproteins were eluted with 100 mM glycine-HCL, pH 2.8 and fractions were immediately neutralized with 1 M Tris base. The gp120 glycoproteins were concentrated using Centriprep 30 spin filters (Amicon), and resuspended in PBS

20 containing protease inhibitors. Protein concentrations were determined by comparison with commercially available gp120 (Agmed) on Coomassie blue-stained SDS-PAGE gels. All of the gp120 preparations were homogenous, with the exception of the BAL gp120 preparation, in which approximately 5 percent

25 of the protein was proteolytically cleaved.

Soluble CD4 proteins [Arthos, J., et al., *Cell* 57:469-481 (1989)] were kindly provided by Dr. Raymond Sweet (SmithKline Beecham). The soluble VCAM protein used in these studies is a chimera of human D1D2 VCAM and the murine

30 constant kappa chain. The soluble VCAM was expressed in SF9 cells by a recombinant baculovirus and purified on a Protein A column.

Gp120 Binding Assay

The YU2ΔC1ΔV1/2ΔC5 protein was iodinated to a specific activity of 900 Ci/mmol using solid-phase lactoperoxidase and glucose oxidase (Enzymobeads, BioRad, Richmond, CA) [Gerard, N.P., et al., *J Biol Chem* 264:1760-1766 (1989)]. The CCR5F-L1.2 cells were preincubated for 10-20 minutes at room temperature in phosphate-buffered saline. Then the labeled protein was added (final concentration 0.1 nM to 5 x 10⁵ cells in duplicate in 100 μl of 50 mM HEPES, pH 7.2 containing 1mM CaCl₂, 5 mM MgCl₂, 0.5% BSA, 100 nM sCD4 and different concentrations of unlabeled YU2ΔC1ΔV1/2ΔC5 or HXBc2ΔC1ΔC5 protein. For chemokine inhibition, the iodinated YU2ΔC1ΔV1/2ΔC5 protein was incubated with the CCR5F-L1.2 cells in the same buffer containing 100 nM sCD4, 100 nM HXBc2ΔC1ΔC5 and different concentrations of RANTES MIP-1α, MIP-1β or the HXBc2ΔC1ΔV1/2/3ΔC5 protein. After 30 minutes of incubation at 37° C, cells were washed in 50 mM HEPES, pH 7.2, 1 mM CaCl₂, 5 mM MgCl₂, 0.5% BSA and 0.5 M NaCl and bound radioactivity counted. The background (non-specific) binding was determined in the presence of 100 nM unlabeled YU2ΔC1ΔV1/2ΔC5 protein. The percent specific binding was calculated using the following formula:

$$\% \text{ Specific Binding} = 100 \times \frac{(S-B)}{(T-B)}$$

where S represents the observed counts bound at a given concentration of unlabeled competitor protein, T represents the observed counts bound in the absence of competitor, and B represents the background counts.

The ability of purified gp120 exterior envelope glycoproteins from macrophage-tropic primary or laboratory-

adapted HIV-1 to compete with the natural ligands for CCR5 was studied in the absence and presence of soluble forms of CD4 [Hussey, R., et al., *Nature* 331:78-81 (1988); Arthos, J., et al., *Cell* 57:469-481 (1989)]. Radiolabeled MIP-1 α ,
5 MIP-1 β and RANTES, but not MCP-1 or IL-8, bound to CCR5F-L1.2 cells, which are murine lymphocytes stably expressing an epitope-tagged CCR5 protein ($5-8 \times 10^4$ binding sites/cell), with dissociation constants of 1.1, 0.4 and 0.2 nM, respectively (data not shown). The HIV-1 gp120
10 derivatives used in this study (Figure 9A) were derived from the JR-FL, BAL and YU2 macrophage-tropic primary viruses or from the HXBc2 laboratory adapted virus. Some of the gp120 glycoproteins contain deletions of the first (C1) and fifth (C5) conserved regions, which are important for the gp120
15 interaction with the gp41 transmembrane glycoprotein [Helseth, E., et al., *J. Virol* 65:2119-2123 (1991)], or deletions of the major V1/V2 or V3 variable loops [Wyatt, R., et al., *J Virol* 67:4557-4565 (1993); Wyatt, R., et al., *J Virol* 69:5723-5733 (1995)]. All of the gp120 derivatives
20 used in this study have been shown to bind CD4 efficiently, with dissociation constants of 4-30 nM and to bind the F105 and 17b antibodies in the absence and presence of soluble CD4, respectively [Wyatt, R., et al., *J Virol* 67:4557-4565 (1993); Wyatt, R., et al., *J Virol* 69:5723-5733 (1995);
25 Ivey-Hoyle, M., *Proc Natl Acad Sci USA* 88:512-516 (1991)]. The F105 antibody recognizes a discontinuous HIV-1 gp120 epitope that overlaps the CD4 binding site [Posner, M., et al., *J Immunol* 146:4325-4332 (1991)], while the 17b antibody binds a discontinuous gp120 epitope that is increased in
30 exposure following CD4 binding [Thali, M., *J Virol* 67:3978-3988 (1993)]. Two soluble forms of the CD4 glycoprotein were included in the study, four-domain soluble CD4 (sCD4) and a protein consisting of the amino-terminal two domains

of CD4 (D1D2 sCD4) [Hussey, R., et al., *Nature* 331:78-81 (1988); Arthos, J., et al., *Cell* 57:469-481 (1989)]. In the presence of sCD4, the JR-FL, BAL and YU2ΔC1ΔV1/2ΔC5 envelope glycoproteins, which were derived from the macrophage-tropic primary viruses, significantly inhibited MIP-1α binding to CCR5F-L1.2 cells (Figure 9B). A dose-response curve indicated inhibitory concentrations (IC₅₀) of 4, 7, 5.5 and 0.7 nM for the JR-FL, BAL and YU2ΔC1ΔV1/2ΔC5 glycoproteins, respectively, in the presence of sCD4 (Figure 9C). In the absence of sCD4, 500 nM concentrations of the JR-FL, BAL and YU2ΔC1ΔV1/2ΔC5 glycoproteins inhibited 32-45 percent of MIP-1α binding to CCR5F-L1.2 cells. For these gp120 derivatives, the presence of sCD4 resulted in a 2- to 3- log increase in the efficiency of the observed inhibition.

In contrast to the above results, the YU2ΔC1ΔV1/2/3ΔC5 glycoprotein, which differs from the YU2ΔC1ΔV1/2ΔC5 glycoprotein by the absence of the gp120 V3 loop, was dramatically reduced in the ability to inhibit MIP-1α binding in the presence and absence of sCD4 (Figure 9B and 9C). Thus, the V3 loop appears to be critical for the inhibition of MIP-1α binding to the CCR5F-L1.2 cells. No significant inhibition of MIP-1α binding was observed for any of the HXBc2 envelope glycoprotein derivatives over that seen with sCD4 alone. The latter inhibition was 12 percent or less and did not significantly increase at higher sCD4 concentrations. The inhibition of MIP-1α binding by the JR-FL, BAL and YU2ΔC1ΔV1/2ΔC5 proteins was specific for CCR5F-L1.2 cells, since no significant inhibition of MIP-1α binding to L1.2 cells expressing CCR1 was observed for these

81

envelope glycoproteins, even when sCD4 was present (Figure 9D). Similarly, no inhibition of MIP-1 α binding to THP-1 cells was seen for these gp120 glycoprotein sCD4 mixtures (data not shown). The THP-1 cells used in these experiments specifically bound MIP-1 α but did not bind MIP-1 β , indicating that CCR5 is not efficiently expressed on the cell surface (L.W., unpublished data). The observed chemokine receptor specificity indicates that interaction with MIP-1 α is not the basis for the observed inhibition of binding by the gp120 glycoprotein-CD4 complexes. The JR-FL, BAL and YU2 Δ C1 Δ V1/2 Δ C5 glycoproteins, but not the YU2 Δ C1 Δ V1/2/3 Δ C5 or the HXBc2 Δ C1 Δ C5 glycoproteins, also inhibited MIP-1 β binding to CCR5F-L1.2 cells in the presence of sCD4 (Figure 9E). Together these results indicate that MIP-1 α and MIP-1 β binding to CCR5-expressing cells can be specifically inhibited by gp120 glycoproteins or some gp120 fragments derived from macrophage-tropic primary HIV-1 isolates, that the efficiency of this inhibition is dramatically increased in the presence of soluble CD4, and that an intact V3 loop appears to be important for the effect.

The two-domain soluble CD4 (D1D2 sCD4) was compared to four-domain sCD4 for the ability to promote the high-affinity interaction with CCR5 when mixed with gp120 glycoproteins from macrophage-tropic primary HIV-1. Mixtures of these gp120 glycoproteins with both D1D2 sCD4 and sCD4 efficiently inhibited MIP-1 α and MIP-1 β binding to CCR5F-L1.2 cells (Figures 10A and B). In contrast to the sCD4 protein, the D1D2 sCD4 inhibited MIP-1 α and MIP-1 β binding with an IC₅₀ of 20-30 nM in the absence of the gp120 glycoprotein. This inhibitory effect of D1D2 sCD4 exhibited

chemokine receptor specificity, since the D1D2 sCD4 did not efficiently inhibit MIP-1 α binding to CCR1-L1.2 cells (Figure 10C). Soluble VCAM, another soluble immunoglobulin family protein, had no significant effect on MIP-1 α binding to CCR5F-L1.2 cells (Figure 10A).

We examined the effect of anti-gp120 monoclonal antibodies on the inhibition of MIP-1 α binding to CCR5F-L1.2 cells by the JR-FL gp 120 glycoprotein in the presence of sCD4 (Figure 11). All of the antibodies included in this study were previously shown to recognize gp120 in the presence of sCD4 [Wyatt, R., et al., *J Virol* 69:5723-5733 (1995); Thali, M., *J Virol* 67:3978-3988 (1993); Moore, J., et al., *J Virol* 69:122-130 (1995); Gershoni J., et al., *FASEB J* 7:1185-1187 (1993)] and were able to precipitate the JR-FL gp120 glycoprotein (data not shown). The 17b neutralizing antibody, which recognizes a discontinuous, conserved gp120 epitope exposed better after CD4 binding [Thali, M., *J Virol* 67:3978-3988 (1993)], blocked the inhibition of MIP-1 α binding by the gp120-sCD4 mixture. Inhibition of MIP-1 α binding was also decreased by the addition of CG10 antibody, which recognizes an epitope present only on gp120-CD4 complexes [Gershoni J., et al., *FASEB J* 7:1185-1187 (1993)]. Two neutralizing antibodies, 19b and Loop 2, which recognize the V3 loop of the JR-FL gp120 glycoprotein [Moore, J., et al., *J Virol* 69:122-130 (1995)], significantly blocked the effect of the JR-FL gp120-CD4 mixture on MIP-1 α binding. In contrast to the above results, nonneutralizing antibodies (A32, C11, 2.3A) that recognize gp120 domains interacting with the gp41 transmembrane glycoprotein [Moore, J., et al., *J Virol* 70:1863-1872 (1996)] did not block the ability of gp120-sCD4 complexes to inhibit MIP-1 α binding. Of the anti-CD4 antibodies tested (5A8, Q425, R3-47 and L71)

[Burkly L., et al., *J Immunol* 149:1779-1787 (1992); Healey, D., et al., *J Exp Med* 172:1233-1242 (1990); Truneh, A., et al., *J Biol Chem* 266:5942-5948 (1991); Bachelder, R., et al., *J Virol* 69:5734-5742 (1995)], only L71, which can
5 decrease gp120-CD4 interaction in some contexts [Truneh, A., et al., *J Biol Chem* 266:5942-5948 (1991)], moderately affected the observed MIP-1 α inhibition.

The direct binding of a radiolabeled macrophage-tropic virus gp120 protein YU2 Δ C1 Δ V1/2 Δ C5, to CCR5F-L1.2 cells was
10 examined in the presence of sCD4. The specific binding of the labeled YU2 Δ C1 Δ V1/2 Δ C5 protein to CCR5F-L1.2 cells was efficiently inhibited by the YU2 Δ C1 Δ V1/2 Δ C5 protein but not by the HXBc2 Δ C1 Δ C5 protein (Figure 12A). Scatchard analysis revealed that the YU2 Δ C1 Δ V1/2 Δ C5 binding occurred
15 with a dissociation constant of 4-6 nM and that the number of binding sites on the CCR5F-L1.2 cells was similar for the YU2 Δ C1 Δ V1/2 Δ C5 protein and for MIP-1 β (data not shown). RANTES, MIP-1 α and MIP-1 β decreased the binding of the YU2 Δ C1 Δ V1/2 Δ C5 protein to CCR5F-L1.2 cells, whereas the V3
20 loop-deleted protein, YU2 Δ C1 Δ V1/2/3 Δ C5, did not (Figure 12B). These results indicate that the natural CCR5 ligands inhibit the binding of a macrophage-tropic HIV-1 gp120-sCD4 complex to CCR5-expressing cells.

This demonstrates that the gp120 glycoproteins derived
25 from macrophage-tropic primary HIV-1 specifically interact with CCR5 and inhibit MIP-1 α or MIP-1 β binding to transfected cells that express CCR5. The gp120-CCR5 interaction was dramatically enhanced by CD4, indicating that a major consequence of CD4 binding is, in addition to
30 virus attachment to the target cell, promotion of subsequent events like chemokine receptor binding that are important

for the membrane fusion process. CD4-mediated induction of CCR5 binding may contribute to the observed enhancement of primary HIV-1 infection by sCD4 [Sullivan, N., et al., *J Virol* 69:4413-4422 (1995)]. A sequential, two-step process for viral attachment and entry allows conserved elements on the viral glycoproteins interacting with chemokine receptors to remain sequestered from antiviral antibodies, until such time as proximity to the target cell membrane is achieved by the virus. The limited accessibility of antibodies to CD4-induced gp120 moieties in the context of the membrane-anchored, oligomeric envelope glycoprotein-CD4 complex may then allow membrane fusion and virus entry to proceed in the face of the humoral immune response.

A low affinity interaction with CCR5 can apparently occur in the absence of CD4 for gp120 variants derived from macrophage-tropic primary HIV-1. These results indicate that a major site for CCR5 interaction is contained on the gp120 glycoprotein. The CCR5-interactive region must be reasonably well-conserved, since CCR5 can be used as a coreceptor by diverse HIV-1 strains as well as by simian immunodeficiency viruses [Choe, H., et al., *Cell* 85:1135-1148 (1996); Marcon, L., et al. submitted]. While additional studies will be required to define this site absolutely precisely, our data provides general information concerning the CCR5-interactive region. First, the CCR5-interactive region is preserved on a gp120 fragment lacking the C1, V1/V2 and C5 regions. Second, some HIV-1-neutralizing antibodies that do not interfere with gp120-CD4 binding blocked the interaction of soluble CD4-gp120 complexes with CCR5. One of these antibodies, 17b, recognizes a discontinuous gp120 epitope that is exposed better upon CD4 binding [Thali, M., *J Virol* 67:3978-3988 (1993)], a property shared by the CCR5-interactive region.

Other antibodies inhibiting CCR5 interaction, 19b and Loop 2 are directed against the gp120 V3 loop [Moore, J., et al., *J Virol* 69:122-130 (1995)]. The 17b and V3 epitopes *per se* cannot represent the CCR5-interactive region on gp120, since natural primate immunodeficiency viruses that are not recognized by the 17b, 19b and Loop 2 antibodies can utilize CCR5 as a coreceptor [Choe, H., et al., *Cell* 85:1135-1148 (1996); Marcon, et al., submitted]. However, CCR5-gp120 interaction is likely to involve gp120 structures proximal to these epitopes. Third, deletion of the V3 loop, which can determine HIV-1 tropism and chemokine receptor utilization [Choe, H., et al., *Cell* 85:1135-1148 (1996); Cheng-Mayer, C., et al., *J Virol* 64:4390-4398 (1990); Chesebro, B., et al., *J Virol* 65:5782-5789 (1991); Hwang, S., et al., *Science* 253:71-74 (1991); Westervelt, P., et al., *J Virol* 66:2577-2582 (1992)], disrupted CCR5 interaction. A component of the chemokine receptor binding site on gp120 may reside in a V3 structure demonstrating moderate variability. Together these observations implicate a discontinuous gp120 structure in the vicinity of the 17b epitope, with a probable contribution from V3 sequences, as the CCR5-interactive moiety on the gp120 glycoprotein. The proximity of the 17b epitope and the V3 loop on the native gp120 glycoprotein has been suggested by previous mutational and antibody competition analyses [Wyatt, R., et al., *J Virol* 69:5723-5733 (1995); Thali, M., *J Virol* 67:3978-3988 (1993); Moore, J., et al., *J Virol* 70:1863-1872 (1996)].

Our results indicate that an interaction between D1D2sCD4 and CCR5 occurs in the absence of gp120 glycoproteins. Since full-length sCD4 did not compete for MIP-1 α and MIP-1 β binding to CCR5-expressing cells at comparable concentrations, the D1D2 sCD4 appears to more efficiently expose a CCR5-interactive region. That a CD4

fragment spontaneously and specifically binds CCR5 raises the possibility that native CD4 sequences directly contribute to a high affinity binding site for CCR5 in the presence of the appropriate gp120 glycoprotein. If the
5 observed D1D2 sCD4-CCR5 interaction is biologically relevant, it is probably not restricted to CCR5, since other chemokine receptors as discussed above can be used as coreceptors for HIV-1 variants [Feng, Y., et al., Science 272:872-877 (1996); Choe, H., et al., Cell 85:1135-1148
10 (1996); Doranze, B.J., et al., Cell 85:1149-1158 (1996)]. The regions of gp120 and CD4 that appear to contribute to CCR5 interaction are expected to be quite distant from the target cell membrane, at least upon initial attachment of the virus to CD4. This implies that significant
15 conformational rearrangements of envelope glycoprotein-CD4 complexes may occur during the course of HIV-1 entry to optimize CCR5 binding. Exploiting the interactive regions and mechanisms should facilitate therapeutic and prophylactic strategies targeting HIV-1 entry.

REFERENCES

- Alkhatib, G., et al., *Science* 272:1955-1958 (1996).
- Ashorn, P., et al., *J. Virol.* 64: 2149-2156 (1990).
- Asjo, B., et al., *Lancet* ii: 660-662 (1986).
- Baggiolin, M., et al., *Adv. Immunol.* 55: 97-179 (1994).
- Barre-Sinoussi, et al., *Science* 220: 868-871 (1983).
- Bergeron, L., et al., *J. Virol.* 66: 2389-2397 (1992).
- Bleul, C.C., et al., *Nature* 382:829-833 (1996).
- Bou-Habib, D., et al., *J. Virol.* 68: 6006-6013 (1994).
- Brand, D., et al., *J. Virol.* 69: 166-171 (1995).
- Broder, C., et al., *Virology* 193: 483-491 (1993) C. Broder, C et al. *Proc. Natl. Acad. Sci. USA* 92, 9004-9008 (1995).
- Burton, D., et al. *Science* 266, 1024-1027 (1994).
- Carrillo, et al., *Virology* 197: 817-824 (1993).
- Chaudhuri, A., et al., *Proc. Natl. Acad. Sci. USA* 29: 10793-10797 (1993).
- Cheng-Mayer, et al., *J. Virol.* 64: 4390-4398 (1990).
- Cheng-Mayer, et al., *Science* 240: 80-82 (1988).
- Chesebro, B. et al. *J. Virol* 64: 215-221 (1990).
- Chesebro, B. et al., *J. Virol.* 65: 5782-5789 (1991).
- Chesebro, B., et al., *J. Virol.* 66: 6547-6554 (1992).
- Choe, H., et al., *Cell* 85:1135-1148 (1996).
- Clapham, P.R., et al., *Virology* 181: 703-715 (1991).
- Cocchi, F., DeVico, et al., *Science* 270: 1811-1815 (1995).
- Collman, R., et al., *J. Virol.* 66:7517-7521 (1992).
- Connor, R.I, et al., *J. Virol.* 67: 1772-1777 (1993).
- Connor, R.I. et al., *J. Virol.* 68: 4400-4408 (1994a).
- Connor, R.I., et al., *AIDS Res. Hum. Retro.* 10: 321-323 (1994b).
- Cullen, B.R. et al., *Methods Enzymol.* 152: 64-73 (1989).

- Cundell, D., et al., *Nature* 377, 435-438 (1995).
- Dalgleish, A.G. et al. *Nature* 312: 763-767 (1984).
- Daugherty, A.G. et al., *J. Exp. Med.* 183:2349-2354 (1996).
- Dean, M., et al. *Science* 273:1856-1862 (1996).
- Deng, H.K., et al., *Nature* 381:661-666 (1996).
- Doranz, B.J., et al., *Cell* 85:1149-1158 (1996).
- Dragic, T., et al., *J. Virol.* 66: 4794-4802 (1992).
- Dragic, T., et al., *Nature* 381:667-673 (1996).
- Fauci, A., et al., *Ann. Int. Med.* 100: 92-106 (1984).
- Federspiel, B., et al., *Genomics* 16: 707-712 (1993).
- Feng, Y., et al., *Science* 272: 872-877 (1996).
- Fenyo, E., et al., *J. Virol.* 62: 4414-4419 (1988).
- Freed, E., et al., *J. Virol.* 65: 190-194 (1991).
- Freedman, A., et al., *J. Exp. Med.* 174: 1661-1664 (1991).
- Gallo, R.C., et al.,
Science 224: 500-503 (1984).
- Gao F., et al., *J. Virol.* 70: 1651-1667 (1996)
- Gartner, S., et al., *Science* 233: 215-219 (1986).
- Gerard, N., et al., *Curr. Opin. Immunol.* 6: 140-145 (1994).
- Goudsmit, J., et al., *Proc. Natl. Acad. Sci. USA* 85: 4478-4482.
- Grimaila, R., *J. Virol.* 66: 1875-1883 (1992).
- Halseth, E et al., *J. Virol.* 64: 2416-2420 (1990).
- Harouse, J.M., et al. *Ann Neurol* 63:2527-2533 (1989).
- He, J. and Landau, N.R. *J. Virol.* 69:4587-4592 (1995).
- Heath, H., et al., *J Clin Invest* (In Press).
- Horuk, R., et al., *Science* 261, 1182-1184 (1993).
- Horuk, R., et al., *Trends Pharmacol. Sci.* 15: 159-165 (1994).
- Hwang S., et al., *Science* 253: 71-74 (1991).
- Ivanoff, L., et al. *Retroviruses* 7: 595-603 (1991).
- Javaherian, K., et al., *Proc. Natl. Acad. Sci. USA* 86: 6768-

- 6772 (1989).
- Jazin, E., et al., *Regulatory Peptides* 47: 247-258 (1993).
- Jordan, C.A., et al., *J. Virol.* 65:736-742 (1991).
- Jose, P.J., et al., *J. Exp. Med.* 179: 881-887 (1994).
- Karlsson, G., et al., *J. Virol.*: in press (1996).
- Kitaura, M., et al., *J. Biol. Chem.* 271: 7725-7730 (1996).
- Klatzmann, D., et al., *Nature* 312: 767-768 (1996).
- Koenig, S., et al., *Science* 233: 1089-1092 (1986).
- Korber, B.T.M., et al., *J. Virol.* 68:7467-7481 (1994).
- Kowalski, M., et al., *Science* 237: 1351-1355 (1987).
- Kunz, D., et al. *J. Biol. Chem* 267: 9101-9106 (1991).
- Leonard C., et al., *J. Biol. Chem.* 265: 10373-10382 (1990).
- Li, Y., et al., *J. Virol.* 65: 3973-3985 (1991).
- Li, Y., et al., *J. Virol.* 66:6587-6600 (1992).
- Liu, R., et al., *Cell* 86:367-377 (1996).
- Lifson, J., et al., *Science* 323: 725-728 (1986).
- Linsley, P., et al., *J. Virol.* 62: 3695-3702 (1988).
- Loetscher, M., et al., *J. Biol Chem.* 269, 232-237 (1994).
- Maddon, P., et al., *Cell* 47: 333-348 (1986).
- Mascola J., et al., *v. Infect. Dis.* 169: 48-54 (1994).
- McDougal, J.S., et al., *Science* 231: 382-385 (1986).
- McKnight, A., et al., *Virology* 201: 8-18 (1994).
- Montefiori, D., et al., *Virology* 182: 635-643 (1991).
- Moore, J., et al., *J. Virol.* 68: 469-484 (1994).
- Moore, J.P., et al., *J. Virol.* 69: 101-109 (1995).
- Myers, G., et al., Los Alamos National Laboratory, Los Alamos, New Mexico (1994).
- Oberlin, E., et al., *Proc Natl Acad Sci USA* 92:700-704 (1996).
- O'Brien, W., et al. *Nature* 348: 69-73 (1990).
- Page, K., et al., *J. Virol.* 66, 524-533 (1992).
- Palermo, D.P., et al., *J. Biotech.* 19, 35-47 (1991).

- Paxton, W.A., *Nature Medicine* 2: 412-417 (1996).
- Ponath, P., et al., *J. Clin. Invest.* 97: 604-612 (1992a).
- Ponath, P., et al., *J. Exp. Med.* 183: 1-12 (1996).
- Pope, M., et al., *Cell* 78: 389-398 (1994).
- Power, C., et al., *J. Virol.* 68:4643-4649 (1994).
- Price, R.W., et al., *Science* 239:586-591 (1988).
- Probst, W., et al., *DNA Cell Biol.* 11: 1-20 (1992).
- Putney, S., et al., *Science* 234: 1392-1395 (1986).
- Raport, C., et al., *J. Biol. Chem.*, in press (1996).
- Rusche, J., et al., *Proc. Natl. Acad. Sci. USA* 85: 3198-3202 (1988).
- Samson, M., et al., *Biochemistry* 35: 3362-3367 (1996).
- Samson, M., et al., *Nature* 382:722-725 (1996).
- Schall, *Curr. Opin. Immunol* 6: 865-873 (1994).
- Schuitemaker, H., et al., *J. Virol.* 65: 356-363 (1991).
- Schmidtmayerova, H., et al., *Proc. Natl. Acad. Sci. USA* 93:700-704 (1996).
- Shi, B., et al., *J. Clin. Invest.* 98:1979-1990 (1996).
- Skinner, M., et al., *Hum. Retrovir.* 4: 187-197. (1988).
- Sodroski J., et al., *Nature* 321: 412-417 (1986).
- Sozzani, S., et al. *J. Immunol.* 155: 3292-3295 (1995).
- Spira, A., et al., *J. Exp. Med.* 183: 215-225 (1996).
- Stein, B., et al., *Cell* 49: 659-668 (1987).
- Strizki, J.M., et al., *J. Virol.* 70:7654-7662 (1996).
- Sullivan, N., et al., *J. Virol.* 69: 4413-4422 (1995).
- Takahashi, K., et al., *Ann Neurol* 39:705-711 (1996).
- Termesett, M., et al., *J. Virol.* 62: 2026-2032 (1988).
- Thali, M., et al., *Nature* 372: 363-365 (1994).
- Tornatore, C., et al., *J. Virol.* 65:6094-6100 (1991).
- Travis, B., et al., *Virology* 186: 313-317 (1992).
- Valentin, A., et al. *J. Virol.* 68: 6684-6689 (1994).
- Watkins, B.A., et al., *Science* 249:549-553 (1990).

- Weissman, D., et al., *Proc. Natl. Acad. Sci. USA* 92: 826-830 (1995).
- Weller, P., et al. *Am. J. Respir. Cell Mol. Biol.* 10: 610-620 (1995).
- Westervelt, P., et al. *Proc. Natl. Acad. Sci. U.S.A.* 88:3097-3101 (1991).
- Westervelt, P., et al., *J. Virol.* 66: 2577-2582 (1991).
- Willey, R.L., et al., *J. Virol.* 68, 4409-4419 (1994).

The above-mentioned references are hereby incorporated herein by reference.

This invention has been described in detail including the preferred embodiments thereof. However, it will be appreciated that those skilled in the art, upon consideration of this disclosure may make modifications and improvements thereon without departing from the spirit and scope of the invention as set forth in the claims.

We claim:

1. A method of inhibiting the infectivity of a primary macrophage-tropic strain of HIV-1 comprising administering a therapeutically effective amount of a molecule that inhibits interaction between said primary macrophage-tropic HIV-1 strain and a β chemokine receptor selected from the group consisting of CCR3 and CCR5.
2. The method of claim 1, wherein said molecule inhibits interaction by binding to said β chemokine receptor.
3. The method of claim 2, wherein said molecule is an antibody to CCR3 or CCR5.
4. The method of claim 3, wherein said antibody binds to a surface-epitope on CCR3 or CCR5.
5. The method of claim 1, wherein said molecule inhibits interaction by serving as a CCR3 or CCR5 decoy to the primary macrophage-tropic HIV-1 strain.
6. The method of claim 1, wherein said molecule is administered prior to sexual contact in a composition containing a pharmaceutically-acceptable carrier.
7. The method of claim 6, wherein said composition is a foam, ointment, cream or gel.
8. A method of facilitating infection of a primary macrophage-tropic strain of HIV-1 comprising transforming a cell by a vector system containing nucleic acid segments encoding CCR3, CCR5, or encoding both CCR3 and CCR5.
9. The method of claim 8, wherein said cell is a CD4⁺ cell.
10. The method of claim 8, wherein said cell is a CD4⁺ cell which further comprises transforming said cell with a vector containing nucleic acid segments encoding CD4.

11. A method of diagnosing susceptibility to HIV infection in a human which comprises obtaining a biological sample containing cells expressing CCR3, CCR5 or CCR3 and CCR5, measuring levels of CCR3 or CCR5, wherein levels of CCR3 or CCR5 greater than a reference level is indicative of increased susceptibility to HIV infection.

12. The method of claim 11, wherein said cells in said biological sample are selected from the group consisting of KG-1A promyeloblastic cells, CD4-positive PBMC, CD8-positive PBMC, myeloid cells, dendritic cells eosinophils and peripheral blood T lymphocytes.

13. The method of claim 12, wherein said cells are eosinophils.

14. The method of claim 12, wherein said cells are dendritic cells and the level of CCR3 is measured.

15. A method of determining prognosis in an HIV-1 infected individual, which comprises measuring levels of CCR3 or CCR5, wherein levels of CCR3 or CCR5 in a biological sample containing cells expressing CCR3 or CCR5 greater than a reference level indicate a higher risk of early onset of AIDS.

16. The method of claim 14, wherein the level of β -chemokines in the biological sample is also measured and compared with a base line level.

17. A transgenic animal expressing human CD4 and CCR3 and/or human CCR5.

18. A method for evaluating the potential efficiency of a test compound as a vaccine or therapeutic to HIV-1 infection which comprises administering a predetermined amount of the test compound to the transgenic animal of claim 1.

19. The transgenic animal of claim 1, wherein said

animal is selected from the group consisting of mice, rats pigs, docs, cats, and rabbits.

20. A method of screening for an inhibitor of HIV-1 infectivity, comprising:

combining a cell bearing CD4 and a β chemokine receptor selected from the group consisting of one or more of CCR3 and CCR5 with a strain of HIV-1 and an agent, and assessing infectivity, wherein decreased infectivity as compared with a suitable control is indicative that the agent is an inhibitor of HIV-1 infectivity.

21. The method of claim 16, wherein the β chemokine receptor is CCR3.

22. A method of treating HIV-infection, comprising administering a therapeutically effective amount of an agent capable of inhibiting the CCR3 mediated HIV infectivity.

23. A method of diagnosis of CCR3-mediated HIV infection, comprising obtaining a primary HIV isolate from an individual, and assessing whether CCR3 can increase infectivity of said isolate, wherein increased infectivity is indicative of a CCR3-mediated infection.

24. A gp120 derivative having a conformational discontinuous chemokine receptor binding site, wherein said conformational discontinuous epitope is defined by amino acid residues present in the gp120 constant region C2, C3 and C4 and variable region V3, and said conformation approximates the conformation of the discontinuous chemokine receptor binding site of wild type gp120 complexed to CD4, wherein exposure of the discontinuous binding site is enhanced by having at least a region of a variable region or constant region of wild type gp120 removed.

25. The gp120 derivative of claim 24 which further

comprises a gp120 CD4 binding site.

26. A stabilized complex of the gp120 derivative of claim 25 bound to a soluble CD4 molecule.

27. The stabilized complex of claim 26, wherein the complex is stabilized by conjugation to a poly(alkylene oxide).

28. A method of inhibiting the infectivity of a strain of HIV-1 comprising administering a therapeutically effective amount of the stabilized complex of claim 26 that inhibits interaction between said HIV-1 strain and a chemokine receptor.

29. The method of claim 28 wherein the chemokine receptor is selected from the group consisting of CCR3, CCR5 and CXCR4.

30. The method of claim 28, wherein the chemokine receptor is CCR5.

31. A method of screening for an inhibitor of HIV-1 infectivity, comprising:

combining a cell bearing a chemokine receptor selected from the group consisting of one or more of CCR3, CCR5 and CXCR4 with a labeled gp120 molecule or a labeled gp120 derivative of claim 25, a soluble CD4 molecule and an agent, and assessing infectivity, wherein decreased infectivity as compared with a suitable control is indicative that the agent is an inhibitor of HIV-1 infectivity.

32. The method of claim 31, wherein the chemokine receptor is CCR5.

FIG. 1A

CD4 (+ CD2 control)




FIG. 1B

CD4 + CCR1F



FIG. 1C

CD4 + CCR3




FIG. 1D

CD4 + CCR5






FIG.2

3 / 26

FIG.3A

CD4 (+ CD2 control)




ADA YU2 89.6 ELI HXBc2 A-MuLV

CD4 + CCR3




ADA YU2 89.6 ELI HXBc2 A-MuLV

CD4 + CCR5



ADA YU2 89.6 ELI HXBc2 A-MuLV

CD4 + HUMSTSR



ADA YU2 89.6 ELI HXBc2 A-MuLV

FIG.3D




FIG.4A




FIG.4B




FIG.4C




FIG.4D

SUBSTITUTE SHEET (RULE 26)

6 / 26





FIG.5

7/26



Plasmid (pg) M 10^3 10^2 10^1 10^0 10^{-1} 10^{-2} 10^{-3} 10^{-4}




FIG. 6A

8 / 26




FIG.6B

SUBSTITUTE SHEET (RULE 26)




FIG. 6C




FIG.7

11/26




FIG.8A

12/26




FIG.8B




FIG.8C




FIG.8D

14/26




FIG. 9A




FIG.9B




FIG.9C

17/26




FIG.9D

18/26




FIG.9E




FIG.10A

20/26




FIG. 10B

21/26




FIG.10C




FIG.11

23/26




FIG.12A

24/26




FIG.12B

25 / 26




FIG.13




FIG.14

SUBSTITUTE SHEET (RULE 26)

26 / 26




FIG.15

| | |
|-------|-----------------------------|
| gpr15 | MDPEETSVYLDYYYATSPN |
| gpr1 | MEDLEETLFEEFENYSYDLDYYSLESD |
| rccr5 | MDYQVSSPTYDIDYYTSEPC |
| ccr5 | MDYQVSSPIYDINYYTSEPC |

FIG.16



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | | |
|--|--|--|--|
| (51) International Patent Classification 6 : C12N 15/09, A61K 39/395, G01N 33/569, 33/68, A01K 67/027, C07K 14/16, A61K 47/48 // C12N 5/10, A61K 38/19, C07K 14/715 | | A3 | (11) International Publication Number: WO 98/00535 (43) International Publication Date: 8 January 1998 (08.01.98) |
| (21) International Application Number: PCT/US97/12701 (22) International Filing Date: 27 June 1997 (27.06.97) (30) Priority Data: 60/020,830 28 June 1996 (28.06.96) US 60/027,931 9 October 1996 (09.10.96) US 60/036,729 24 January 1997 (24.01.97) US (71) Applicants (for all designated States except US): DANA-FARBER CANCER INSTITUTE [US/US]; 44 Binney Street, Boston, MA 02115 (US). LEUKOSITE, INC. [US/US]; 215 First Street, Cambridge, MA 02142 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): SODROSKI, Joseph, G. [US/US]; 10 Ashland Street, Medford, MA 02155 (US). NEWMAN, Walter [US/US]; Apartment 3, 3 Durham Street, Boston, MA 02115 (US). CHOE, Hye-Ryun [KR/US]; 25 Webster Avenue #203, Somerville, MA 02143 (US). WU, LiJun [US/US]; 139 Oak Street, Reading, MA 01867 (US). GERARD, Norma [US/US]; 117 Walpole Street, Dover, MA 02030 (US). GERARD, Craig [US/US]; 117 Walpole Street, Dover, MA 02030 (US). | | (74) Agents: EISENSTEIN, Ronald, I. et al.; Dike, Bronstein, Roberts & Cushman, LLP, 130 Water Street, Boston, MA 02109 (US). (81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments. (88) Date of publication of the international search report: 18 June 1998 (18.06.98) | |
| (54) Title: METHOD FOR INHIBITING HIV-1 INFECTION, DRUG SCREENS, AND METHODS OF DIAGNOSIS AND PROGNOSIS OF SUSCEPTIBILITY TO HIV INFECTION | | | |
| (57) Abstract Novel β chemokine receptors that facilitate cellular entry of primary macrophage-tropic HIV-1 strains are described. CCR5 and CCR3 broadly facilitate entry of macrophage-tropic HIV-1 strains. A gp120 conformational binding site that is formed by the binding of gp120 and CD4 which permits binding of the complex to the chemokine receptors is also disclosed. Binding assays which permit the ready screening for molecules which affect the binding of gp120 and the chemokine are taught as well as specific targets for affecting the binding. | | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | | | TR | Turkey |
| BG | Bulgaria | HU | Hungary | ML | Mali | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MN | Mongolia | UA | Ukraine |
| BR | Brazil | IL | Israel | MR | Mauritania | UG | Uganda |
| BY | Belarus | IS | Iceland | MW | Malawi | US | United States of America |
| CA | Canada | IT | Italy | MX | Mexico | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NE | Niger | VN | Viet Nam |
| CG | Congo | KE | Kenya | NL | Netherlands | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NO | Norway | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | NZ | New Zealand | | |
| CM | Cameroon | | | PL | Poland | | |
| CN | China | KR | Republic of Korea | PT | Portugal | | |
| CU | Cuba | KZ | Kazakstan | RO | Romania | | |
| CZ | Czech Republic | LC | Saint Lucia | RU | Russian Federation | | |
| DE | Germany | LI | Liechtenstein | SD | Sudan | | |
| DK | Denmark | LK | Sri Lanka | SE | Sweden | | |
| EE | Estonia | LR | Liberia | SG | Singapore | | |

INTERNATIONAL SEARCH REPORT

Intern. Appl. No.

PCT/US 97/12701

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/09 A61K39/395 G01N33/569 G01N33/68 A01K67/027
C07K14/16 A61K47/48 //C12N5/10, A61K38/19, C07K14/715

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| X | T. DRAGIC ET AL.: "HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5." NATURE, vol. 381, no. 6584, 20 June 1996, LONDON, GB, pages 667-673, XP002061246 cited in the application see the whole document --- | 8-12, 15, 16, 20 |
| X | H. DENG ET AL.: "Identification of a major co-receptor for primary isolates of HIV-1." NATURE, vol. 381, no. 6584, 20 June 1996, LONDON, GB, pages 661-666, XP002061247 see the whole document --- | 1-11, 15-20 |
| | -/- | |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

2 April 1998

Date of mailing of the international search report

22. 04. 1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Nooij, F

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 97/12701

| C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT | | |
|--|---|-----------------------|
| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
| A | <p>J. MOORE ET AL.: "Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein or human immunodeficiency virus type 1 are highly prevalent in sera of infected humans." JOURNAL OF VIROLOGY, vol. 67, no. 2, February 1993, BALTIMORE, MD, USA, pages 863-875, XP002061248 cited in the application see abstract</p> | 24,25 |
| A | <p style="text-align: center;">---</p> <p>M. THALI ET AL.: "Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding." JOURNAL OF VIROLOGY, vol. 67, no. 7, July 1993, BALTIMORE, MD, USA, pages 3978-3988, XP002061249 cited in the application see abstract</p> | 24,25 |
| A | <p style="text-align: center;">---</p> <p>WO 94 26305 A (AKZO NOBEL NV) 24 November 1994 see the whole document</p> | 1-32 |
| P,X | <p style="text-align: center;">---</p> <p>H. CHOE ET AL.: "The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates." CELL, vol. 85, no. 7, 28 June 1996, CAMBRIDGE, MA, USA, pages 1135-1148, XP002061250 cited in the application see abstract see figure 4</p> | 8-12,15, 16,20 |
| P,X | <p style="text-align: center;">---</p> <p>L. WU ET AL.: "CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5." NATURE, vol. 384, no. 6605, 14 November 1996, LONDON, GB, pages 179-183, XP002061251 see the whole document</p> <p style="text-align: center;">---</p> <p style="text-align: center;">-/--</p> | 24-30 |

INTERNATIONAL SEARCH REPORT

Intern... nal Application No

PCT/US 97/12701

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|----------------------------|
| P,X | L. WU ET AL.: "CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro." THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 185, no. 9, 5 May 1997, NEW YORK, NY, USA, pages 1681-1691, XP002061252 see the whole document --- | 1-4,11, 12,15, 16,20 |
| P,A | S. WAIN-HOBSON: "One on one meets two." NATURE, vol. 384, no. 6605, 14 November 1996, LONDON, GB, pages 117-118, XP002061253 see figure ----- | 1-32 |

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 97/12701

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 97/12701

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Remark : Although claims 1-7, 22, 28-30 are directed to a method of treatment of the human/animal body, and although claim 18 is directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/12701

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|---|---------------------|----------------------------|---------------------|
| WO 9426305 A | 24-11-94 | AU 680916 B | 14-08-97 |
| | | AU 6907394 A | 12-12-94 |
| | | CA 2160922 A | 24-11-94 |
| | | EP 0699077 A | 06-03-96 |
| | | JP 8510246 T | 29-10-96 |
| | | US 5518723 A | 21-05-96 |
| ----- | | | |